Case number 1:22-cv-01395
Novartis Pharmaceuticals Corporation v. MSN Pharmaceuticals Inc., et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Jul 11, 2025 | 526 | Notice of Appeal* (1) |
| Jul 1, 2025 | 508 | ORAL ORDER: The redactions filed at D.I. 503 , 504 , and 505 as supported by the Declaration at D.I. 507 are APPROVED. Ordered by Judge Richard G. Andrews on 7/1/2025. (nms) (Entered: 07/01/2025) (0) |
| Jun 30, 2025 | 503 | REDACTED VERSION of 484 Opening Brief in Support, by Novartis Pharmaceuticals Corporation. (O'Brien, Daniel) (Entered: 06/30/2025) (28) |
| Jun 30, 2025 | 504 | REDACTED VERSION of 485 Declaration, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit 201, # 2 Exhibit 202, # 3 Exhibit 203)(O'Brien, Daniel) (Entered: 06/30/2025) (0) |
| Jun 30, 2025 | 505 | REDACTED VERSION of 486 Declaration by Novartis Pharmaceuticals Corporation. (O'Brien, Daniel) (Entered: 06/30/2025) (30) |
| Jun 30, 2025 | 506 | REDACTED VERSION of 487 Declaration, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 101, # 16 Exhibit 102, # 17 Exhibit 103, # 18 Exhibit 104, # 19 Exhibit 105, # 20 Exhibit 106, # 21 Exhibit 107, # 22 Exhibit 108, # 23 Exhibit 109, # 24 Exhibit 110, # 25 Exhibit 111, # 26 Exhibit 112, # 27 Exhibit 113, # 28 Exhibit 114, # 29 Exhibit 115, # 30 Exhibit 116, # 31 Exhibit 117, # 32 Exhibit 118)(O'Brien, Daniel) Modified on 7/1/2025 (nms). (Entered: 06/30/2025) (0) |
| Jun 30, 2025 | 507 | DECLARATION of Brian Robinson Regarding Redactions to Novartis's Motion for Injunctive Relief Against MSN re 503 Redacted Document, 505 Redacted Document, 504 Redacted Document by Novartis Pharmaceuticals Corporation. (O'Brien, Daniel) (Entered: 06/30/2025) (6) |
| Jun 27, 2025 | 500 | ANSWERING BRIEF in Opposition re 483 MOTION for Injunctive Relief Against MSN filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc..Reply Brief due date per Local Rules is 7/7/2025. (Weinblatt, Richard) (Entered: 06/27/2025) (26) |
| Jun 27, 2025 | 501 | [SEALED] DECLARATION of DeForest McDuff, Ph.D. re 500 Answering Brief in Opposition, by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc.. (Attachments: # 1 Certificate of Service)(Weinblatt, Richard) Modified on 6/27/2025 (nms). (Entered: 06/27/2025) (0) |
| Jun 27, 2025 | 502 | [SEALED] DECLARATION of Richard Juang re 500 Answering Brief in Opposition, by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V, # 23 Exhibit W, # 24 Certificate of Service)(Weinblatt, Richard) Modified on 6/27/2025 (nms). (Entered: 06/27/2025) (0) |
| Jun 26, 2025 | 499 | SO ORDERED Granting Joint Stipulation and Proposed Order regarding schedule for submission of final judgment with respect to U.S. Patent No. 11, 096,918 (see Order for further details). Signed by Judge Richard G. Andrews on 6/26/2025. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA(nms) (Entered: 06/26/2025) (2) |
| Jun 25, 2025 | 498 | Joint letter to The Honorable Richard G. Andrews, from the Parties, regarding request for final judgment submission schedule. (Attachments: # 1 Proposed Order)(O'Brien, Daniel) Modified on 6/25/2025 (nms). (Entered: 06/25/2025) (0) |
| Jun 24, 2025 | 497 | SO ORDERED Granting 496 STIPULATION and Proposed Order (*Reset Briefing Schedule: re 483 MOTION for Injunctive Relief Against MSN. Answering Brief due 6/27/2025). Signed by Judge Richard G. Andrews on 6/24/2025. (nms) (Entered: 06/24/2025) (2) |
| Jun 23, 2025 | 494 | REDACTED VERSION of 482 Proposed Consent Judgment by Novartis Pharmaceuticals Corporation. (O'Brien, Daniel) (Entered: 06/23/2025) (4) |
| Jun 23, 2025 | 495 | REDACTED VERSION of 493 Consent Judgment, by Novartis Pharmaceuticals Corporation. (O'Brien, Daniel) (Entered: 06/23/2025) (4) |
| Jun 23, 2025 | 496 | STIPULATION and Proposed Order to Extend Time - filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc.. (Weinblatt, Richard) Modified on 6/24/2025 (nms). (Entered: 06/23/2025) (2) |
| Jun 17, 2025 | 493 | [SEALED] CONSENT JUDGMENT between Novartis Pharmaceuticals Corporation and Gerbera Therapeutics Inc. and Nanjing Noratech Pharmaceutical Co.. Signed by Judge Richard G. Andrews on 6/17/2025.*This order has been emailed to local counsel. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA, 1:23-cv-00401-RGA(nms) (Entered: 06/17/2025) (0) |
| Jun 16, 2025 | 490 | STIPULATION and [Proposed] Order to Extend Time to File Redacted Versions, by Novartis Pharmaceuticals Corporation. (O'Brien, Daniel) Modified on 6/16/2025 (nms). (Entered: 06/16/2025) (2) |
| Jun 16, 2025 | 491 | REDACTED VERSION of 481 Letter by Novartis Pharmaceuticals Corporation. (O'Brien, Daniel) (Entered: 06/16/2025) (2) |
| Jun 16, 2025 | 492 | STIPULATION and [Proposed] Order to Extend Time to File Redacted Version, by Novartis Pharmaceuticals Corporation. (O'Brien, Daniel) Modified on 6/16/2025 (nms). (Entered: 06/16/2025) (2) |
| Jun 10, 2025 | 488 | REDACTED VERSION of 477 Letter by Novartis Pharmaceuticals Corporation. (O'Brien, Daniel) (Entered: 06/10/2025) (2) |
| Jun 10, 2025 | 489 | Letter to The Honorable Richard G. Andrews, from Richard C. Weinblatt, regarding Novartis's Motion for Injunctive Relief Against MSN. (Weinblatt, Richard) Modified on 6/11/2025 (nms). (Entered: 06/10/2025) (2) |
| Jun 9, 2025 | 481 | [SEALED] Joint letter to The Honorable Richard G. Andrews, from the Parties, regarding status. (O'Brien, Daniel) Modified on 6/10/2025 (nms). (Entered: 06/09/2025) (0) |
| Jun 9, 2025 | 482 | [SEALED] Proposed Consent Judgment and Order of Injunction, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certificate of Service)(O'Brien, Daniel) Modified on 6/9/2025 (nms). (Entered: 06/09/2025) (0) |
| Jun 9, 2025 | 483 | MOTION for Injunctive Relief Against MSN - filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Proposed Order, # 2 Proposed Order, # 3 Certificate of Service)(O'Brien, Daniel) Modified on 6/10/2025 (nms). (Entered: 06/09/2025) (0) |
| Jun 9, 2025 | 484 | [SEALED] OPENING BRIEF in Support re 483 MOTION for Injunctive Relief Against MSN, filed by Novartis Pharmaceuticals Corporation. Answering Brief/Response due date per Local Rules is 6/23/2025. (Attachments: # 1 Certificate of Service)(O'Brien, Daniel) Modified on 6/10/2025 (nms). (Entered: 06/09/2025) (0) |
| Jun 9, 2025 | 485 | [SEALED] DECLARATION of Daniel DiMeo in Support of 484 Opening Brief in Support, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit 201, # 2 Exhibit 202, # 3 Exhibit 203, # 4 Certificate of Service)(O'Brien, Daniel) Modified on 6/10/2025 (nms). (Entered: 06/09/2025) (0) |
| Jun 9, 2025 | 486 | [SEALED] DECLARATION of John C. Jarosz in Support of 484 Opening Brief in Support, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certificate of Service)(O'Brien, Daniel) Modified on 6/10/2025 (nms). (Entered: 06/09/2025) (0) |
| Jun 9, 2025 | 487 | [SEALED] DECLARATION of Carrie S. Park in Support of 484 Opening Brief in Support, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 101, # 16 Exhibit 102, # 17 Exhibit 103, # 18 Exhibit 104, # 19 Exhibit 105, # 20 Exhibit 106, # 21 Exhibit 107, # 22 Exhibit 108, # 23 Exhibit 109, # 24 Exhibit 110, # 25 Exhibit 111, # 26 Exhibit 112, # 27 Exhibit 113, # 28 Exhibit 114, # 29 Exhibit 115, # 30 Exhibit 116, # 31 Exhibit 117, # 32 Exhibit 118, # 33 Certificate of Service)(O'Brien, Daniel) Modified on 6/10/2025 (nms). (Entered: 06/09/2025) (0) |
| Jun 5, 2025 | 480 | Letter to The Honorable Richard G. Andrews, from Richard C. Weinblatt, regarding response to Novartis's June 4, 2025, letter. (Weinblatt, Richard) Modified on 6/5/2025 (nms). (Entered: 06/05/2025) (3) |
| Jun 4, 2025 | 479 | Letter to The Honorable Richard G. Andrews, from Daniel A. O'Brien, regarding Novartis's request for a trial decision and entry of final judgment related to U.S. Patent No. 11,096,918. (Attachments: # 1 Proposed Order)(O'Brien, Daniel) Modified on 6/4/2025 (nms). (Entered: 06/04/2025) (0) |
| Jun 3, 2025 | 477 | [SEALED] Joint Letter to The Honorable Richard G. Andrews, from the Parties, regarding Status. (O'Brien, Daniel) (Entered: 06/03/2025) (0) |
| Jun 3, 2025 | 478 | REDACTED VERSION of 476 Letter by Novartis Pharmaceuticals Corporation. (O'Brien, Daniel) (Entered: 06/03/2025) (2) |
| May 27, 2025 | 476 | [SEALED] Joint letter to The Honorable Richard G. Andrews, from the Parties, regarding status. (O'Brien, Daniel) Modified on 5/28/2025 (nms). (Entered: 05/27/2025) (0) |
| May 22, 2025 | 475 | REDACTED VERSION of 471 Letter by Novartis Pharmaceuticals Corporation. (O'Brien, Daniel) (Entered: 05/22/2025) (2) |
| May 20, 2025 | 474 | NOTICE OF SUBSTITUTION OF COUNSEL re Novartis Pharmaceuticals Corporation: Entry of appearance of attorney Daniel A. O'Brien. Attorney Daniel M. Silver and Alexandra M. Joyce terminated. (O'Brien, Daniel) (Entered: 05/20/2025) (3) |
| May 16, 2025 | 472 | REDACTED VERSION of 467 Letter, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 5/19/2025 (nms). (Entered: 05/16/2025) (2) |
| May 16, 2025 | 473 | REDACTED VERSION of 469 Letter, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 5/16/2025 (nms). (Entered: 05/16/2025) (2) |
| May 15, 2025 | 471 | [SEALED] Joint letter to The Honorable Richard G. Andrews, from the Parties, regarding status. (Attachments: # 1 Certificate of Service)(Silver, Daniel) Modified on 5/15/2025 (nms). (Entered: 05/15/2025) (0) |
| May 12, 2025 | 470 | STIPULATION and Proposed Order to Extend Time to submit a public redacted version of Joint Letter (D.I. 1861 in 20-md-2930; D.I. 469 in 22-1395; and D.I. 191 in 23-401) to May 16, 2025 - filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 5/13/2025 (nms). (Entered: 05/12/2025) (3) |
| May 5, 2025 | 469 | [SEALED] Joint letter to The Honorable Richard G. Andrews, from the Parties, regarding status. (Attachments: # 1 Certificate of Service)(Silver, Daniel) Modified on 5/5/2025 (nms). (Entered: 05/05/2025) (0) |
| May 2, 2025 | 468 | STIPULATION and Proposed Order to Extend Time to submit a public redacted version of the joint letter to The Honorable Richard G. Andrews from the Parties Regarding Case Status to May 16, 2025 - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 5/2/2025 (nms). (Entered: 05/02/2025) (3) |
| Apr 25, 2025 | 467 | [SEALED] Joint Letter to The Honorable Richard G. Andrews, from The Parties, regarding status. (Attachments: # 1 Certificate of Service)(Silver, Daniel) Modified on 4/25/2025 (nms). (Entered: 04/25/2025) (0) |
| Feb 12, 2025 | 465 | Letter to The Honorable Richard G. Andrews, from Daniel M. Silver, Esq., enclosing electronic versions of post-trial documents. (Silver, Daniel) Modified on 2/13/2025 (nms). (Entered: 02/12/2025) (1) |
| Feb 12, 2025 | 466 | REDACTED VERSION of 464 Notice of Lodging of Defendants' Trial Demonstratives, by Gerbera Therapeutics Inc., Nanjing Noratech Pharmaceutical Co., Limited. (Attachments: # 1 Exhibit 5, # 2 Exhibit 6)(Gattuso, Dominick) Modified on 2/12/2025 (nms). (Entered: 02/12/2025) (0) |
| Feb 11, 2025 | 463 | NOTICE of Lodging of Defendants' Trial Demonstratives by Gerbera Therapeutics Inc., Nanjing Noratech Pharmaceutical Co., Limited (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4)(Gattuso, Dominick) (Entered: 02/11/2025) (0) |
| Feb 11, 2025 | 464 | [SEALED] NOTICE of Lodging of Defendants' Trial Demonstratives by Gerbera Therapeutics Inc., Nanjing Noratech Pharmaceutical Co., Limited (Attachments: # 1 Exhibit 5, # 2 Exhibit 6, # 3 Certificate of Service)(Gattuso, Dominick) (Entered: 02/11/2025) (0) |
| Feb 7, 2025 | 462 | POST-TRIAL Reply Brief Regarding U.S. Patent No. 11,096,918, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 2/7/2025 (nms). (Entered: 02/07/2025) (25) |
| Feb 5, 2025 | 461 | Letter to The Honorable Richard G. Andrews, from Richard C. Weinblatt, enclosing electronic versions of post-trial documents. (Weinblatt, Richard) Modified on 2/5/2025 (nms). (Entered: 02/05/2025) (1) |
| Jan 31, 2025 | 459 | Answering Brief Regarding Non-Infringement of the '918 Patent, by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, Gerbera Therapeutics Inc., Nanjing Noratech Pharmaceutical Co., Limited, MSN Pharmaceuticals Inc.. (Weinblatt, Richard) Modified on 1/31/2025 (nms). (Entered: 01/31/2025) (30) |
| Jan 31, 2025 | 460 | Proposed Findings of Fact by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, Gerbera Therapeutics Inc., Nanjing Noratech Pharmaceutical Co., Limited, MSN Pharmaceuticals Inc.. (Weinblatt, Richard) (Entered: 01/31/2025) (30) |
| Jan 29, 2025 | 458 | SO ORDERED Granting Stipulation and Order Regarding Submission of Admitted Exhibits Cited in Post-Trial Briefing (D.I. 165 in 23-cv-401-RGA; D.I. 457 in 22-cv-1395-RGA; D.I. 1754 in 20-md-2930-RGA). Signed by Judge Richard G. Andrews on 1/29/2025. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA, 1:23-cv-00401-RGA(nms) (Entered: 01/29/2025) (4) |
| Jan 28, 2025 | 457 | STIPULATION and Order Regarding Submission of Admitted Exhibits Cited in Post-Trial Briefing by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 01/28/2025) (4) |
| Jan 22, 2025 | 455 | STIPULATION and Order Regarding Post-Trial Briefing, by MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc., MSN Laboratories Private Limited. (Weinblatt, Richard) Modified on 1/22/2025 (nms). (Entered: 01/22/2025) (4) |
| Jan 22, 2025 | 456 | SO ORDERED Granting Stipulation and Order Regarding Post-Trial Briefing (D.I. 162 in 23-cv-401-RGA; D.I. 455 in 22-cv-1395-RGA; D.I. 1749 in 20-md-2930-RGA). Signed by Judge Richard G. Andrews on 1/22/2025. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA, 1:23-cv-00401-RGA(nms) (Entered: 01/22/2025) (4) |
| Jan 21, 2025 | 454 | MOTION to Modify the Post-Trial Briefing Schedule - filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Weinblatt, Richard) Modified on 1/21/2025 (nms). (Entered: 01/21/2025) (0) |
| Jan 13, 2025 | 453 | MANDATE of USCA as to 240 Notice of Appeal (Federal Circuit), filed by Novartis Pharmaceuticals Corporation. USCA Decision: Affirmed. (Attachments: # 1 Opinion, # 2 Judgment)(nms) (Entered: 01/13/2025) (0) |
| Jan 10, 2025 | 450 | Letter to The Honorable Richard G. Andrews, from Daniel M. Silver, Esq., regarding electronic versions of post-trial documents. (Silver, Daniel) Modified on 1/10/2025 (nms). (Entered: 01/10/2025) (1) |
| Jan 3, 2025 | 448 | OPENING Post-Trial Brief for U.S. Patent No. 11,096,918, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 1/3/2025 (nms). (Entered: 01/03/2025) (30) |
| Jan 3, 2025 | 449 | Proposed Findings of Fact by Novartis Pharmaceuticals Corporation. (Silver, Daniel) (Entered: 01/03/2025) (30) |
| Dec 31, 2024 | 443 | Official Transcript of Bench Trial held on 12/09/24 before Judge Richard G. Andrews. Court Reporter/Transcriber Heather M. Triozzi,Email: Heather_Triozzi@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 1/21/2025. Redacted Transcript Deadline set for 1/31/2025. Release of Transcript Restriction set for 3/31/2025. (Triozzi, Heather) (Entered: 12/31/2024) (341) |
| Dec 31, 2024 | 444 | Official Transcript of Bench Trial held on 12/10/24 before Judge Richard G. Andrews. Court Reporter/Transcriber Heather M. Triozzi,Email: Heather_Triozzi@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 1/21/2025. Redacted Transcript Deadline set for 1/31/2025. Release of Transcript Restriction set for 3/31/2025. (Triozzi, Heather) (Entered: 12/31/2024) (311) |
| Dec 31, 2024 | 445 | Official Transcript of Bench Trial held on 12/11/24 before Judge Richard G. Andrews. Court Reporter/Transcriber Heather M. Triozzi,Email: Heather_Triozzi@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 1/21/2025. Redacted Transcript Deadline set for 1/31/2025. Release of Transcript Restriction set for 3/31/2025. (Triozzi, Heather) (Entered: 12/31/2024) (206) |
| Dec 31, 2024 | 446 | Official Transcript of Bench Trial held on 12/12/24 before Judge Richard G. Andrews. Court Reporter/Transcriber Heather M. Triozzi,Email: Heather_Triozzi@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 1/21/2025. Redacted Transcript Deadline set for 1/31/2025. Release of Transcript Restriction set for 3/31/2025. (Triozzi, Heather) (Entered: 12/31/2024) (188) |
| Dec 31, 2024 | 447 | Official Transcript of Bench Trial held on 12/13/24 before Judge Richard G. Andrews. Court Reporter/Transcriber Heather M. Triozzi,Email: Heather_Triozzi@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 1/21/2025. Redacted Transcript Deadline set for 1/31/2025. Release of Transcript Restriction set for 3/31/2025. (Triozzi, Heather) (Entered: 12/31/2024) (131) |
| Dec 20, 2024 | 442 | Admitted Trial Exhibits for Bench Trial held 12/10/2024 - 12/13/2024, Regarding U.S. Patent Nos. 11,058,667 and 11,096,918, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 12/20/2024 (nms). (Entered: 12/20/2024) (21) |
| Dec 18, 2024 | 437 | STIPULATION and Order Regarding Post-Trial Briefing by Novartis Pharmaceuticals Corporation. (Silver, Daniel) (Entered: 12/18/2024) (6) |
| Dec 18, 2024 | 438 | SO ORDERED Granting (D.I. 1694 in 20-md-2930-RGA; D.I. 143 in 23-cv-401-RGA; D.I. 437 in 22-cv-1395-RGA) Stipulation and Order Regarding Post-Trial Briefing. Signed by Judge Richard G. Andrews on 12/18/2024. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA, 1:23-cv-00401-RGA(nms) (Entered: 12/18/2024) (6) |
| Dec 18, 2024 | 439 | REDACTED VERSION of 390 Proposed Pretrial Order, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 12/18/2024 (nms). (Entered: 12/18/2024) (30) |
| Dec 18, 2024 | 440 | REDACTED VERSION of 433 Amended Exhibits, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 12/19/2024 (nms). (Entered: 12/18/2024) (24) |
| Dec 18, 2024 | 441 | NOTICE of Lodging of MSN's Demonstratives used at the trial held 12/9/2024, through 12/13/2024, by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3)(Weinblatt, Richard) Modified on 12/19/2024 (nms). (Entered: 12/18/2024) (0) |
| Dec 13, 2024 | 436 | STIPULATION and Proposed Order to Extend Time to submit a redacted public version of Amended Exhibits 6-M and 8 to Joint Pretrial Order Regarding U.S. Patent Nos. 11,096,918 and 11,058,667 (D.I. 1690) to December 18, 2024 - filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 12/16/2024 (nms). (Entered: 12/13/2024) (3) |
| Dec 10, 2024 | 434 | MOTION for Exemption of Persons from the District of Delaware's May 17, 2024 Standing Order on Personal Devices - filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Text of Proposed Order)(Silver, Daniel) (Entered: 12/10/2024) (0) |
| Dec 10, 2024 | 435 | ORDER Granting Motion for Exemption of Persons from the District of Delaware's May 17, 2024 Standing Order on Personal Devices (D.I. 434 in 22-cv-1395-RGA; D.I. 1691 in 20-md-2930-RGA; D.I. 140 in 23-cv-401-RGA). Signed by Judge Richard G. Andrews on 12/10/2024. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA, 1:23-cv-00401-RGA(nms) (Entered: 12/10/2024) (2) |
| Dec 8, 2024 | 431 | MOTION for Pro Hac Vice Appearance of Attorney Susanne L. Flanders - filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certification)(Joyce, Alexandra) (Entered: 12/08/2024) (0) |
| Dec 8, 2024 | 432 | Pro Hac Vice Fee - Credit Card Payment received for Susanne L. Flanders. ( re 431 MOTION for Pro Hac Vice Appearance of Attorney Susanne L. Flanders )( Payment of $ 50, receipt number ADEDC-4564882).(Joyce, Alexandra) (Entered: 12/08/2024) (0) |
| Dec 8, 2024 | 433 | [SEALED] Amended Exhibits 6-M and 8 to Pretrial Order (D.I. 390 ), by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit 6-M, # 2 Exhibit 8, # 3 Certificate of Service)(Joyce, Alexandra) Modified on 12/9/2024 (nms). (Entered: 12/08/2024) (0) |
| Dec 5, 2024 | 425 | Letter to The Honorable Richard G. Andrews, from Richard C. Weinblatt, regarding response to Novartis's December 4, 2024 Letter. (Attachments: # 1 Exhibit G, # 2 Exhibit H)(Weinblatt, Richard) Modified on 12/5/2024 (nms). (Entered: 12/05/2024) (0) |
| Dec 5, 2024 | 426 | ORAL ORDER: I have read three letters concerning two unidentified FDA internal documents. (No. 20-2930, D.I. 1671, 1680, 1682). (From perusing the attachments, it appears the documents are the "Assessment Cycle" and the "Drug Product Quality Assessment." D.I. 1680-1, Exh. D, at 61 of 95). The movant, MSN, has not submitted an order that would implement its request, if granted. This is not insignificant given the vagueness of the request. Neither side addresses the fact that the protective order at issue in this dispute was issued by the District Court for the District of Columbia. I am loathe to de-designate documents that are confidential pursuant to another court's order. Neither the letters nor the redacted D.D.C. brief (D.I. 1671-1) give much of a hint about what the significance of the two internal documents might be. Presumably, this is because neither side has seen the two documents, so there is only speculation about what the two documents might contain. In other words, this is just an extremely late discovery request. Trial starts in less than two business days. To the extent the documents contain any relevant information, the experts have not considered the information. Counsel for Novartis in the D.D.C. case appears to have agreed to produce the disputed documents, but then reneged when Novartis overruled its outside lawyers in that case. (D.I. 1680-1, Exh. D, at 52-55 of 95). Novartis's letter does not comment on this. (D.I. 1680). Based on the foregoing, and notwithstanding Novartis's lack of defense of its own actions, MSN's request is DENIED. Ordered by Judge Richard G. Andrews on 12/5/2024. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA(nms) (Entered: 12/05/2024) (0) |
| Dec 5, 2024 | 427 | ORDER of USCA as to 240 Notice of Appeal (Federal Circuit) filed by Novartis Pharmaceuticals Corporation. Decision of USCA: On August 13, 2024, Novartis Pharmaceuticals Corporation ("Novartis") moved pursuant to Federal Rule of Appellate Procedure 8 to enjoin, pending appeal, MSN Pharmaceuticals, Inc., MSN Laboratories Private Ltd., and MSN Life Sciences Private Ltd. (collectively, "MSN") from the commercial marketing and sale of its generic version of Novartis's Entresto product. See ECF No. 4. On August 14, 2024, this court temporarily enjoined MSN from the commercial marketing and sale of its generic version of Entresto while the court considered the Rule 8 motion. See ECF No. 8. On December 4, 2024, the court entered judgment resolving the underlying appeal. See ECF No. 80. Upon consideration of Novartis's motion, IT IS ORDERED THAT: (1) The Rule 8 motion is denied as moot. (2) The temporary relief provided in the court's August 14, 2024 order is lifted. (nms) (Entered: 12/05/2024) (2) |
| Dec 5, 2024 | 428 | ORDER: The Motion for Exemption of Persons from the District of Delaware's May 17, 2024 Standing Order on Personal Devices (D.I. 1678 in 20-md-2930-RGA; D.I. 133 in 23-cv-401-RGA; D.I. 421 in 22-cv-1395-RGA) is GRANTED. Signed by Judge Richard G. Andrews on 12/5/2024. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA, 1:23-cv-00401-RGA(nms) (Entered: 12/05/2024) (2) |
| Dec 5, 2024 | 429 | ORDER: The Motion for Exemption from the District of Delaware's May 17, 2024 Standing Order on Personal Devices (D.I. 1681 in 20-md-2930-RGA; D.I. 424 in 22-cv-1395-RGA) is GRANTED as modified. Signed by Judge Richard G. Andrews on 12/5/2024. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA(nms) (Entered: 12/05/2024) (2) |
| Dec 5, 2024 | 430 | ORDER: The Motion for Exemption from the District of Delaware's May 17, 2024 Standing Order on Personal Devices (D.I. 131 in 23-cv-401-RGA; D.I. 419 in 22-cv-1395-RGA; D.I. 1676 in 20-md-2930-RGA) is GRANTED as modified. Signed by Judge Richard G. Andrews on 12/5/2024. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA, 1:23-cv-00401-RGA(nms) (Entered: 12/05/2024) (2) |
| Dec 4, 2024 | 416 | Letter to The Honorable Richard G. Andrews from Richard C. Weinblatt regarding Curriculum Vitae of Defendants MSN Pharmaceuticals Inc., MSN Laboratories Private Limited, and MSN Life Sciences Private Limited's Experts. (Weinblatt, Richard) (Entered: 12/04/2024) (1) |
| Dec 4, 2024 | 417 | ORDER AFTER PRETRIAL CONFERENCE: The Proposed Pretrial Order (D.I. 1641 ) is ADOPTED, as modified by any discussion at the pretrial conference.The motion in limine to preclude MSN's written description and enablement arguments (D.I. 1639 ) is DENIED. The motion in limine to preclude reference to evidence and "court comments" from the Hetero case (D.I. 1637 ) is GRANTED. The motion in limine to preclude Dr. Spinale from "referencing his undocumented treatment practices" (D.I. 1638 ) is DENIED. (see Order for further details). Signed by Judge Richard G. Andrews on 12/4/2024. (aas) (Entered: 12/04/2024) (3) |
| Dec 4, 2024 | 418 | Letter to The Honorable Richard G. Andrews, from Richard C. Weinblatt, regarding Federal Circuit Opinion. (Attachments: # 1 Opinion)(Weinblatt, Richard) Modified on 12/4/2024 (nms). (Entered: 12/04/2024) (0) |
| Dec 4, 2024 | 419 | MOTION for Exemption from the District of Delaware's May 17, 2024 Standing Order on Personal Devices - filed by Gerbera Therapeutics Inc., Nanjing Noratech Pharmaceutical Co., Limited. (Attachments: # 1 Proposed Order)(Gattuso, Dominick) Modified on 12/4/2024 (nms). (Entered: 12/04/2024) (0) |
| Dec 4, 2024 | 420 | MOTION for Pro Hac Vice Appearance of Attorney Erin Belfield - filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certification of Erin Belfield)(Joyce, Alexandra) (Entered: 12/04/2024) (0) |
| Dec 4, 2024 | 421 | MOTION for Exemption of Persons from the District of Delaware's May 17, 2024 Standing Order on Personal Devices - filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Text of Proposed Order)(Silver, Daniel) (Entered: 12/04/2024) (0) |
| Dec 4, 2024 | 422 | Pro Hac Vice Fee - Credit Card Payment received for Erin Belfield. ( re 420 MOTION for Pro Hac Vice Appearance of Attorney Erin Belfield )( Payment of $ 50, receipt number ADEDC-4562444).(Silver, Daniel) (Entered: 12/04/2024) (0) |
| Dec 4, 2024 | 423 | Letter to The Honorable Richard G. Andrews, from Daniel M. Silver, Esq, regarding response to MSN's December 3, 2024, letter. (Attachments: # 1 Exhibits A-F)(Silver, Daniel) Modified on 12/4/2024 (nms). (Entered: 12/04/2024) (0) |
| Dec 4, 2024 | 424 | MOTION for Exemption from the District of Delaware's May 17, 2024 Standing Order on Personal Devices - filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Weinblatt, Richard) Modified on 12/5/2024 (nms). (Entered: 12/04/2024) (0) |
| Dec 3, 2024 | 411 | Letter to The Honorable Richard G. Andrews, from Daniel M. Silver, Esq., regarding curriculum vitae for Novartis experts. (Silver, Daniel) Modified on 12/3/2024 (nms). (Entered: 12/03/2024) (1) |
| Dec 3, 2024 | 412 | REDACTED VERSION of 409 Expert Report, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 12/3/2024 (nms). (Entered: 12/03/2024) (15) |
| Dec 3, 2024 | 413 | Letter to The Honorable Richard G. Andrews, from Dominick T. Gattuso, Esq., regarding curriculum vitae of Defendants Gerbera Therapeutics, Inc.'s and Nanjing Noratech Pharmaceutical Co., Ltd.'s experts. (Gattuso, Dominick) Modified on 12/3/2024 (nms). (Entered: 12/03/2024) (1) |
| Dec 3, 2024 | 414 | Letter to The Honorable Richard G. Andrews, from Richard C. Weinblatt, regarding FDA's Analysis and findings with respect to the solid state form of MSN's Sacubitril/Valsartan API. (Attachments: # 1 Exhibit A)(Weinblatt, Richard) Modified on 12/3/2024 (nms). (Entered: 12/03/2024) (0) |
| Dec 3, 2024 | 415 | ORAL ORDER: Plaintiff is directed to respond to Defendants' letter dated 12/3/2024 (D.I. 414 in 22-cv-1395-RGA; D.I. 1671 in 20-md-2930-RGA) by COB 12/4/2024. Ordered by Judge Richard G. Andrews on 12/3/2024. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA(nms) (Entered: 12/03/2024) (0) |
| Dec 2, 2024 | 410 | Official Transcript of Pretrial Conference held on 11/22/24 before Judge Richard G. Andrews. Court Reporter Heather M. Triozzi,Email: Heather_Triozzi@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 12/23/2024. Redacted Transcript Deadline set for 1/2/2025. Release of Transcript Restriction set for 3/3/2025. (Triozzi, Heather) (Entered: 12/02/2024) (100) |
| Nov 26, 2024 | 405 | Pro Hac Vice Fee - Credit Card Payment received for Avery Hitchcock. ( re 404 MOTION for Pro Hac Vice Appearance of Attorney Avery Hitchcock )( Payment of $ 50, receipt number ADEDC-4557357).(Gattuso, Dominick) (Entered: 11/26/2024) (0) |
| Nov 26, 2024 | 406 | REDACTED VERSION of 392 Letter, by Gerbera Therapeutics Inc., Nanjing Noratech Pharmaceutical Co., Limited. (Gattuso, Dominick) Modified on 11/26/2024 (nms). (Entered: 11/26/2024) (6) |
| Nov 26, 2024 | 407 | REDACTED VERSION of 393 Declaration, by Gerbera Therapeutics Inc., Nanjing Noratech Pharmaceutical Co., Limited. (Gattuso, Dominick) Modified on 11/26/2024 (nms). (Entered: 11/26/2024) (30) |
| Nov 26, 2024 | 408 | REDACTED VERSION of 391 Letter, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 11/26/2024 (nms). (Entered: 11/26/2024) (18) |
| Nov 26, 2024 | 409 | [SEALED] Sur-SurReply Report of Adam J. Matzger, Ph.D., filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certificate of Service)(Silver, Daniel) Modified on 11/27/2024 (nms). (Entered: 11/26/2024) (0) |
| Nov 25, 2024 | 402 | REDACTED VERSION of 388 MOTION Novartis's and MSN's Combined Briefing for Novartis's Motion In Limine to Preclude MSN's Written Description and Enablement Invalidity Arguments, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 11/25/2024 (nms). (Entered: 11/25/2024) (11) |
| Nov 25, 2024 | 403 | REDACTED VERSION of 389 Appendix, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 11/25/2024 (nms). (Entered: 11/25/2024) (30) |
| Nov 25, 2024 | 404 | MOTION for Pro Hac Vice Appearance of Attorney Avery Hitchcock - filed by Gerbera Therapeutics Inc., Nanjing Noratech Pharmaceutical Co., Limited. (Gattuso, Dominick) (Entered: 11/25/2024) (4) |
| Nov 22, 2024 | 401 | REDACTED VERSION of 387 Defendants Motion in Limine No. 1: To Preclude, by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, Gerbera Therapeutics Inc., Nanjing Noratech Pharmaceutical Co., Limited, MSN Pharmaceuticals Inc.. (Gattuso, Dominick) Modified on 11/22/2024 (nms). (Entered: 11/22/2024) (30) |
| Nov 21, 2024 | 398 | MOTION for Exemption of Persons from the District of Delaware's May 17, 2024 Standing Order on Personal Devices - filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Proposed Order)(Silver, Daniel) (Entered: 11/21/2024) (0) |
| Nov 21, 2024 | 399 | STIPULATION TO EXTEND TIME to file a redacted version of the Pretrial Order to December 18, 2024 - filed by Gerbera Therapeutics Inc., Nanjing Noratech Pharmaceutical Co., Limited. (Gattuso, Dominick) (Entered: 11/21/2024) (3) |
| Nov 21, 2024 | 400 | ORDER: The Motion for Exemption of Persons from the District of Delaware's May 17, 2024 Standing Order on Personal Devices (D.I. 398 in 22-cv-1395-RGA; D.I. 121 in 23-cv-401-RGA; D.I. 1649 in 20-md-2930-RGA) is GRANTED. Signed by Judge Richard G. Andrews on 11/21/2024. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA, 1:23-cv-00401-RGA(nms) (Entered: 11/21/2024) (2) |
| Nov 20, 2024 | 395 | REDACTED VERSION of 384 Letter, by Gerbera Therapeutics Inc., Nanjing Noratech Pharmaceutical Co., Limited. (Gattuso, Dominick) Modified on 11/20/2024 (nms). (Entered: 11/20/2024) (5) |
| Nov 20, 2024 | 396 | REDACTED VERSION of 385 Declaration, by Gerbera Therapeutics Inc., Nanjing Noratech Pharmaceutical Co., Limited. (Gattuso, Dominick) Modified on 11/20/2024 (nms). (Entered: 11/20/2024) (30) |
| Nov 20, 2024 | 397 | Letter to The Honorable Richard G. Andrews, from Daniel M. Silver, Esq., regarding response to Defendants' letter (D.I. 392 ). (Attachments: # 1 Exhibits E-F, # 2 Proposed Order)(Silver, Daniel) Modified on 11/21/2024 (nms). (Entered: 11/20/2024) (0) |
| Nov 19, 2024 | 391 | [SEALED] Letter to The Honorable Richard G. Andrews, from Daniel M. Silver, Esq., regarding response to Gerbera and Noratech's November 15, 2024, letter (D.I. 384 ). (Attachments: # 1 Exhibits 14-16, # 2 Certificate of Service)(Silver, Daniel) Modified on 11/19/2024 (nms). (Entered: 11/19/2024) (0) |
| Nov 19, 2024 | 392 | [SEALED] Letter to The Honorable Richard G. Andrews, from Dominick T. Gattuso, Esq., regarding supplemental expert report after court-ordered production. (Attachments: # 1 Certificate of Service)(Gattuso, Dominick) Modified on 11/19/2024 (nms). (Entered: 11/19/2024) (0) |
| Nov 19, 2024 | 393 | [SEALED] DECLARATION re 392 Letter, by Gerbera Therapeutics Inc., Nanjing Noratech Pharmaceutical Co., Limited. (Attachments: # 1 Certificate of Service, # 2 Exhibit A, # 3 Exhibit B, # 4 Exhibit C, # 5 Exhibit D)(Gattuso, Dominick) Modified on 11/19/2024 (nms). (Entered: 11/19/2024) (0) |
| Nov 19, 2024 | 394 | PROPOSED ORDER to 392 Letter, by Gerbera Therapeutics Inc., Nanjing Noratech Pharmaceutical Co., Limited. (Gattuso, Dominick) Modified on 11/19/2024 (nms). (Entered: 11/19/2024) (2) |
| Nov 18, 2024 | 387 | [SEALED] MOTION in Limine No. 1: To Preclude Novartis and Its Witnesses from Referencing Evidence and Court Comments from the Hetero Matter - filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, Gerbera Therapeutics Inc., Nanjing Noratech Pharmaceutical Co., Limited, MSN Pharmaceuticals Inc.. (Attachments: # 1 Defendants' Exhibits, # 2 Plaintiff's Exhibits, # 3 Certificate of Service)(Gattuso, Dominick) Modified on 11/18/2024 (nms). (Entered: 11/18/2024) (0) |
| Nov 18, 2024 | 388 | [SEALED] MOTION Novartis's and MSN's Combined Briefing for Novartis's Motion In Limine to Preclude MSN's Written Description and Enablement Invalidity Arguments - filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certificate of Service)(Silver, Daniel) (Entered: 11/18/2024) (0) |
| Nov 18, 2024 | 389 | [SEALED] APPENDIX re 388 Motion In Limine to Preclude MSN's Written Description and Enablement Invalidity Arguments, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit A-E, # 2 Certificate of Service)(Silver, Daniel) Modified on 11/18/2024 (nms). (Entered: 11/18/2024) (0) |
| Nov 18, 2024 | 390 | [SEALED] Proposed Pretrial Order by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit 1A, # 2 Exhibit 1A-N, # 3 Exhibit 1B, # 4 Exhibit 2A, # 5 Exhibit 2A-M, # 6 Exhibit 2A-N, # 7 Exhibit 2B, # 8 Exhibit 3A, # 9 Exhibit 3A-N, # 10 Exhibit 3B, # 11 Exhibit 4A, # 12 Exhibit 4B, # 13 Exhibit 5A, # 14 Exhibit 5B, # 15 Exhibit 6, # 16 Exhibit 6-M, # 17 Exhibit 6-N, # 18 Exhibit 7, # 19 Exhibit 7-M, # 20 Exhibit 7-N, # 21 Exhibit 8, # 22 Exhibit 9A, # 23 Exhibit 9B, # 24 Exhibit 10A, # 25 Exhibit 10B, # 26 Exhibit 11A, # 27 Exhibit 11B, # 28 Exhibit 12A, # 29 Exhibit 12B)(Silver, Daniel) (Entered: 11/18/2024) (0) |
| Nov 15, 2024 | 384 | [SEALED] Letter to The Honorable Richard G. Andrews, from Dominick T. Gattuso, Esq., regarding protective order and discovery disputes. (Gattuso, Dominick) Modified on 11/15/2024 (nms). (Additional attachment(s) added on 11/18/2024: # 2 Certificate of Service) (nms). (Entered: 11/15/2024) (0) |
| Nov 15, 2024 | 385 | [SEALED] DECLARATION re 384 Letter, by Gerbera Therapeutics Inc., Nanjing Noratech Pharmaceutical Co., Limited. (Attachments: # 1 Certificate of Service, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Exhibit 7, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13)(Gattuso, Dominick) Modified on 11/15/2024 (nms). (Entered: 11/15/2024) (0) |
| Nov 15, 2024 | 386 | PROPOSED Order regarding to discovery disputes (D.I. 384 in 22-cv-1395-RGA; 1634 in 20-md-2930-RGA), by Gerbera Therapeutics Inc., Nanjing Noratech Pharmaceutical Co., Limited. (Gattuso, Dominick) Modified on 11/18/2024 (nms). (Entered: 11/15/2024) (2) |
| Nov 14, 2024 | 381 | Letter to The Honorable Richard G. Andrews, from Daniel M. Silver, Esq., regarding response to Defendants' November 13, 2024, letter. (Silver, Daniel) Modified on 11/14/2024 (nms). (Additional attachment(s) added on 11/14/2024: # 2 Exhibit E) (nms). (Entered: 11/14/2024) (0) |
| Nov 14, 2024 | 382 | MOTION for Pro Hac Vice Appearance of Attorney Kevin E. Warner - filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc.. (Weinblatt, Richard) (Main Document 382 replaced on 11/15/2024) (aas). (Entered: 11/14/2024) (4) |
| Nov 14, 2024 | 383 | Pro Hac Vice Fee - Credit Card Payment received for Kevin E. Warner. ( re 382 MOTION for Pro Hac Vice Appearance of Attorney Kevin E. Warner )( Payment of $ 50, receipt number ADEDC-4549021).(Weinblatt, Richard) (Entered: 11/14/2024) (0) |
| Nov 13, 2024 | 380 | Letter to The Honorable Richard G. Andrews, from Dominick T. Gattuso, regarding response to Tt Court's November 8, 2024 Memorandum Order (D.I. 375 ). (Attachments: # 1 Exhibits A-D)(Gattuso, Dominick) Modified on 11/13/2024 (nms). (Entered: 11/13/2024) (0) |
| Nov 12, 2024 | 377 | Letter to The Honorable Richard A. Andrews, from Dominick T. Gattuso, Esq., enclosing declaration in support of redactions (D.I. 369 ; D.I. 367 ). (Attachments: # 1 Declaration)(Gattuso, Dominick) Modified on 11/12/2024 (nms). (Entered: 11/12/2024) (0) |
| Nov 12, 2024 | 378 | REDACTED VERSION of 348 Letter, by Gerbera Therapeutics Inc., Nanjing Noratech Pharmaceutical Co., Limited. (Gattuso, Dominick) Modified on 11/12/2024 (nms). (Entered: 11/12/2024) (30) |
| Nov 12, 2024 | 379 | REDACTED VERSION of 360 Declaration, by Gerbera Therapeutics Inc., Nanjing Noratech Pharmaceutical Co., Limited. (Gattuso, Dominick) Modified on 11/12/2024 (nms). (Entered: 11/12/2024) (30) |
| Nov 8, 2024 | 374 | REDACTED VERSION of 341 Letter, by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc.. (Weinblatt, Richard) Modified on 11/8/2024 (nms). (Entered: 11/08/2024) (21) |
| Nov 8, 2024 | 375 | MEMORANDUM ORDER: The Daubert Motions (D.I. 1555 , 1559 ) are DENIED without prejudice to any specific objections at trial. (See Memorandum Order for further details). Signed by Judge Richard G. Andrews on 11/8/2024. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA (aas) (Entered: 11/08/2024) (8) |
| Nov 8, 2024 | 376 | NOTICE OF SERVICE of Defendants MSN Pharmaceuticals Inc., MSN Laboratories Private Limited, and MSN Life Sciences Private Limiteds Notice Pursuant to 35 U.S.C. § 282 filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc..(Weinblatt, Richard) (Entered: 11/08/2024) (2) |
| Nov 7, 2024 | 373 | REDACTED VERSION of 349 Declaration, by Gerbera Therapeutics Inc., MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc., Nanjing Noratech Pharmaceutical Co., Limited. (Gattuso, Dominick) Modified on 11/7/2024 (nms). (Entered: 11/07/2024) (30) |
| Nov 4, 2024 | 372 | ORAL ORDER: The redacted filings (D.I. 367 , 369 ) are REJECTED because parts of them are redacted in their entirety. Absent a compelling reason, supported by a statement under oath by a party, redactions in their entirety are impermissible; redactions must be done so as to redact the least possible amount of the materials submitted. Failure to make a good faith attempt at such redactions may result in sanctions, the most common of which would be simply unsealing the entire filing. Redacting in its entirety a document, or parts of it, that contains publicly available materials is prima facie evidence of bad faith. Revised redacted filings are DUE within five business days. Ordered by Judge Richard G. Andrews on 11/4/2024. (nms) (Entered: 11/04/2024) (0) |
| Nov 3, 2024 | 370 | REDACTED VERSION of 345 Answering Brief in Opposition, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 11/4/2024 (nms). (Entered: 11/03/2024) (26) |
| Nov 3, 2024 | 371 | REDACTED VERSION of 346 Declaration, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 11/4/2024 (nms). (Entered: 11/03/2024) (30) |
| Nov 1, 2024 | 364 | REDACTED VERSION of 361 Reply Brief, by Gerbera Therapeutics Inc., MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc., Nanjing Noratech Pharmaceutical Co., Limited. (Weinblatt, Richard) Modified on 11/1/2024 (nms). (Entered: 11/01/2024) (15) |
| Nov 1, 2024 | 365 | REDACTED VERSION of 362 Declaration, by Gerbera Therapeutics Inc., MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc., Nanjing Noratech Pharmaceutical Co., Limited. (Attachments: # 1 Exhibit 13, # 2 Exhibit 14, # 3 Exhibit 15, # 4 Exhibit 16, # 5 Exhibit 17, # 6 Certificate of Service)(Weinblatt, Richard) Modified on 11/1/2024 (nms). (Entered: 11/01/2024) (0) |
| Nov 1, 2024 | 366 | REDACTED VERSION of 347 Answering Brief in Opposition, by Gerbera Therapeutics Inc., MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc., Nanjing Noratech Pharmaceutical Co., Limited. (Gattuso, Dominick) Modified on 11/1/2024 (nms). (Entered: 11/01/2024) (30) |
| Nov 1, 2024 | 367 | REDACTED VERSION of 348 Declaration, by Gerbera Therapeutics Inc., MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc., Nanjing Noratech Pharmaceutical Co., Limited. (Gattuso, Dominick) Modified on 11/1/2024 (nms). (Entered: 11/01/2024) (30) |
| Nov 1, 2024 | 368 | REDACTED VERSION of 359 Reply Brief, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 11/4/2024 (nms). (Entered: 11/01/2024) (16) |
| Nov 1, 2024 | 369 | REDACTED VERSION of 360 Declaration, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 11/4/2024 (nms). (Entered: 11/01/2024) (30) |
| Oct 30, 2024 | 363 | STIPULATION and Proposed Order to Extend Time to file redacted versions of answering briefs and declarations by November 1, 2024 - filed by Gerbera Therapeutics Inc., Nanjing Noratech Pharmaceutical Co., Limited. (Gattuso, Dominick) Modified on 10/30/2024 (nms). (Entered: 10/30/2024) (3) |
| Oct 25, 2024 | 359 | [SEALED] REPLY BRIEF re 310 MOTION to Exclude the Trial Testimony of Defendants' Experts Dr. Richard McCreery, Dr. Clare Strachan, and Dr. Jonathan Steed Under Fed. R. Evid. 702 and Daubert filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certificate of Service)(Silver, Daniel) (Entered: 10/25/2024) (0) |
| Oct 25, 2024 | 360 | [SEALED] DECLARATION of Gregory J. Manas re 359 Reply Brief, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibits 1-6, # 2 Certificate of Service)(Silver, Daniel) Modified on 10/25/2024 (nms). (Entered: 10/25/2024) (0) |
| Oct 25, 2024 | 361 | [SEALED] REPLY BRIEF re 314 DAUBERT Motion to Exclude Testimony and Materials of Aeri Park, PH.D, filed by Gerbera Therapeutics Inc., MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc., Nanjing Noratech Pharmaceutical Co., Limited. (Weinblatt, Richard) Modified on 10/25/2024 (nms). (Entered: 10/25/2024) (0) |
| Oct 25, 2024 | 362 | [SEALED] DECLARATION of Matthew M. Kamps re 361 Reply Brief, by Gerbera Therapeutics Inc., MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc., Nanjing Noratech Pharmaceutical Co., Limited. (Attachments: # 1 Exhibit 13, # 2 Exhibit 14, # 3 Exhibit 15, # 4 Exhibit 16, # 5 Exhibit 17, # 6 Certificate of Service)(Weinblatt, Richard) Modified on 10/25/2024 (nms). (Entered: 10/25/2024) (0) |
| Oct 23, 2024 | 358 | REDACTED VERSION of 331 Letter, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 10/23/2024 (nms). (Entered: 10/23/2024) (16) |
| Oct 22, 2024 | 353 | STIPULATION and Proposed Order to Extend Time to file redacted versions of answering briefs and the declarations by October 30, 2024 - filed by Gerbera Therapeutics Inc., Nanjing Noratech Pharmaceutical Co., Limited. (Gattuso, Dominick) Modified on 10/22/2024 (nms). (Entered: 10/22/2024) (3) |
| Oct 22, 2024 | 354 | REDACTED VERSION of 326 Opening Brief in Support, by Gerbera Therapeutics Inc., Nanjing Noratech Pharmaceutical Co., Limited. (Gattuso, Dominick) Modified on 10/23/2024 (nms). (Entered: 10/22/2024) (25) |
| Oct 22, 2024 | 355 | REDACTED VERSION of 316 Declaration, by Gerbera Therapeutics Inc., Nanjing Noratech Pharmaceutical Co., Limited. (Gattuso, Dominick) Modified on 10/23/2024 (nms). (Entered: 10/22/2024) (30) |
| Oct 22, 2024 | 356 | REDACTED VERSION of 312 Opening Brief in Support, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 10/23/2024 (nms). (Entered: 10/22/2024) (27) |
| Oct 22, 2024 | 357 | REDACTED VERSION of 313 Declaration, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 10/23/2024 (nms). (Entered: 10/22/2024) (30) |
| Oct 21, 2024 | 350 | ORDER: The Motion to Amend the Complaint and Add Demand for Jury Trial as to MSN Defendants (D.I. 1569 in 20-md-2930-RGA; D.I. 324 in 22-cv-1395-RGA) is DENIED. Signed by Judge Richard G. Andrews on 10/21/2024. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA(nms) (Entered: 10/21/2024) (2) |
| Oct 21, 2024 | 351 | ORDER: Defendant's motion (D.I. 1568 in 20-md-2930-RGA; D.I. 323 in 22-cv-1395-RGA) is GRANTED. Plaintiff Novartis Pharmaceuticals Corporation is required to produce, by November 1, 2024, all tests results (and accompanying notebooks) conducted by Dr. Matzger on MSN's ANDA Products, APIs, and excipients related to ANDA No. 213748. Signed by Judge Richard G. Andrews on 10/21/2024. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA(aas) (Entered: 10/21/2024) (1) |
| Oct 21, 2024 | 352 | NOTICE to Take Deposition of Adam J. Matzger, Ph.D. on October 23, 2024 filed by Nanjing Noratech Pharmaceutical Co., Limited.(Gattuso, Dominick) (Entered: 10/21/2024) (2) |
| Oct 18, 2024 | 342 | REDACTED VERSION of 328 Letter, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 10/18/2024 (nms). (Entered: 10/18/2024) (30) |
| Oct 18, 2024 | 343 | REDACTED VERSION of 329 Letter, by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc.. (Weinblatt, Richard) Modified on 10/18/2024 (nms). (Additional attachment(s) added on 10/21/2024: # 1 Proposed Order) (nms). Modified on 10/21/2024 (nms). (Entered: 10/18/2024) (0) |
| Oct 18, 2024 | 344 | REDACTED VERSION of 330 Letter, by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc.. (Weinblatt, Richard) Modified on 10/18/2024 (nms). (Entered: 10/18/2024) (0) |
| Oct 18, 2024 | 345 | [SEALED] ANSWERING BRIEF in Opposition to 314 Daubert Motion to Exclude Testimony and Materials of Aeri Park Ph.D., filed by Novartis Pharmaceuticals Corporation. Reply Brief due date per Local Rules is 10/25/2024. (Attachments: # 1 Certificate of Service)(Silver, Daniel) Modified on 10/18/2024 (nms). (Entered: 10/18/2024) (0) |
| Oct 18, 2024 | 346 | [SEALED] DECLARATION of Gregory J. Manas re 345 Answering Brief in Opposition, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibits 1-12, # 2 Certificate of Service)(Silver, Daniel) Modified on 10/18/2024 (nms). (Entered: 10/18/2024) (0) |
| Oct 18, 2024 | 347 | [SEALED] ANSWERING BRIEF in Opposition re 310 MOTION to Exclude the Trial Testimony of Defendants' Experts Dr. Richard McCreery, Dr. Clare Strachan, and Dr. Jonathan Steed Under Fed. R. Evid. 702 and Daubert filed by Gerbera Therapeutics Inc., MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc., Nanjing Noratech Pharmaceutical Co., Limited.Reply Brief due date per Local Rules is 10/25/2024. (Attachments: # 1 Certificate of Service)(Gattuso, Dominick) (Entered: 10/18/2024) (0) |
| Oct 18, 2024 | 348 | [SEALED] DECLARATION of Matthew M. Kamps re 347 Answering Brief in Opposition, Gerbera Therapeutics Inc., MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc., Nanjing Noratech Pharmaceutical Co., Limited. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Certificate of Service)(Gattuso, Dominick) Modified on 10/18/2024 (nms). (Entered: 10/18/2024) (0) |
| Oct 18, 2024 | 349 | [SEALED] DECLARATION of Richard Juang re 347 Answering Brief in Opposition, by Gerbera Therapeutics Inc., MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc., Nanjing Noratech Pharmaceutical Co., Limited. (Attachments: # 1 Exhibit G, # 2 Exhibit H, # 3 Exhibit I, # 4 Exhibit J, # 5 Certificate of Service)(Gattuso, Dominick) Modified on 10/18/2024 (nms). (Entered: 10/18/2024) (0) |
| Oct 17, 2024 | 332 | MOTION for Exemption of Persons from the District of Delaware's May 17, 2024 Standing Order on Personal Devices - filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) (Entered: 10/17/2024) (4) |
| Oct 17, 2024 | 333 | Official Transcript of Discovery Dispute Conference held on 9/9/24 before Judge Richard G. Andrews. Court Reporter Heather M. Triozzi,Email: Heather_Triozzi@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 11/7/2024. Redacted Transcript Deadline set for 11/18/2024. Release of Transcript Restriction set for 1/15/2025. (Triozzi, Heather) (Entered: 10/17/2024) (42) |
| Oct 17, 2024 | 334 | MOTION for Exemption of Persons from the District of Delaware's May 17, 2024 Standing Order on Personal Devices - filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc.. (Weinblatt, Richard) (Entered: 10/17/2024) (2) |
| Oct 17, 2024 | 335 | REDACTED VERSION of 322 Letter, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 10/17/2024 (nms). (Entered: 10/17/2024) (30) |
| Oct 17, 2024 | 336 | REDACTED VERSION of 324 MOTION to Amend Complaint and Add Demand for Jury Trial as to MSN Defendants, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 part 2)(Joyce, Alexandra) Modified on 10/17/2024 (nms). (Entered: 10/17/2024) (0) |
| Oct 17, 2024 | 337 | REDACTED VERSION of 325 Letter, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 10/17/2024 (nms). (Entered: 10/17/2024) (7) |
| Oct 17, 2024 | 338 | REDACTED VERSION of 323 Letter, by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc.. (Attachments: # 1 Exhibit A)(Weinblatt, Richard) Modified on 10/17/2024 (nms). (Entered: 10/17/2024) (0) |
| Oct 17, 2024 | 339 | ORDER Granting MOTION for Exemption of Persons from the District of Delaware's May 17, 2024 Standing Order on Personal Devices (D.I. 1578 in 20-md-2930-RGA; D.I. 332 in 22-cv-1395-RGA). Signed by Judge Richard G. Andrews on 10/17/2024. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA(nms) (Entered: 10/17/2024) (2) |
| Oct 17, 2024 | 340 | SO ORDERED Granting MOTION for Exemption of Persons from the District of Delaware's May 17, 2024 Standing Order on Personal Devices (D.I. 1579 in 20-md-2930-RGA; D.I. 334 in 22-cv-1395-RGA) Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA(nms) (Entered: 10/17/2024) (2) |
| Oct 17, 2024 | 341 | [SEALED] Letter to The Honorable Richard G. Andrews, from Richard C. Weinblatt, regarding MSN's responsive letter. (Weinblatt, Richard) Modified on 10/18/2024 (nms). (Entered: 10/17/2024) (0) |
| Oct 15, 2024 | 331 | [SEALED] Letter to The Honorable Richard G. Andrews, from Daniel M. Silver, Esq., regarding subsequent development on pending motions. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Certificate of Service)(Silver, Daniel) Modified on 10/17/2024 (nms). (Entered: 10/15/2024) (0) |
| Oct 11, 2024 | 328 | [SEALED] Letter to The Honorable Richard G. Andrews, from Daniel M. Silver, Esq., regarding Novartis's response to MSN's October 9, 2024 discovery dispute letter. (Attachments: # 1 Exhibits 1-6, # 2 Proposed Order, # 3 Certificate of Service)(Silver, Daniel) Modified on 10/11/2024 (nms). (Entered: 10/11/2024) (0) |
| Oct 11, 2024 | 329 | [SEALED] Letter to The Honorable Richard G. Andrews, from Richard C. Weinblatt, regarding Plaintiff's discovery dispute. (Attachments: # 1 Proposed Order)(Weinblatt, Richard) (Main Document 329 replaced on 10/12/2024) (nms). Modified on 10/12/2024 (nms). (Entered: 10/11/2024) (0) |
| Oct 11, 2024 | 330 | [SEALED] Letter to The Honorable Richard G. Andrews from Defendants regarding Novartis' Request to Amend Complaint - re (1569 in 1:20-md-02930-RGA, 324 in 1:22-cv-01395-RGA) MOTION to Amend Complaint and Add Demand for Jury Trial as to MSN Defendants. (Attachments: # 1 Text of Proposed Order)(Weinblatt, Richard) (Entered: 10/11/2024) (0) |
| Oct 10, 2024 | 326 | [SEALED] OPENING BRIEF in Support re 314 MOTION DEFENDANTS' DAUBERT MOTION TO EXCLUDE TESTIMONY AND MATERIALS OF AERI PARK, PH.D filed by Gerbera Therapeutics Inc., MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc., Nanjing Noratech Pharmaceutical Co., Limited.Answering Brief/Response due date per Local Rules is 10/24/2024. (Attachments: # 1 Certificate of Service)(Gattuso, Dominick) (Entered: 10/10/2024) (0) |
| Oct 10, 2024 | 327 | STIPULATION and Proposed Order to Extend Time to file redacted versions to October 22, 2024 - filed by Gerbera Therapeutics Inc., Nanjing Noratech Pharmaceutical Co., Limited. (Gattuso, Dominick) Modified on 10/10/2024 (nms). (Entered: 10/10/2024) (3) |
| Oct 9, 2024 | 321 | UNSECURED Bond for Injunction Pending Appeal, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 10/9/2024 (nms). (Entered: 10/09/2024) (4) |
| Oct 9, 2024 | 322 | [SEALED] Letter to The Honorable Richard G. Andrews, from Daniel M. Silver, Esq., regarding discovery dispute. (Attachments: # 1 Exhibits A-F, # 2 Proposed Order, # 3 Certificate of Service) (Silver, Daniel) Modified on 10/9/2024 (nms). (Entered: 10/09/2024) (0) |
| Oct 9, 2024 | 323 | [SEALED] Letter to The Honorable Richard G. Andrews, from Richard C. Weinblatt, regarding MSN's discovery dispute. (Attachments: # 1 Exhibit A, # 2 Proposed Order)(Weinblatt, Richard) Modified on 10/9/2024 (nms). (Entered: 10/09/2024) (0) |
| Oct 9, 2024 | 324 | [SEALED] MOTION to Amend Complaint and Add Demand for Jury Trial as to MSN Defendants - filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Proposed Order, # 2 7.1.1. Certification, # 3 Exhibit 1, # 4 Exhibit A, # 5 Exhibit B, # 6 Exhibit C, # 7 Exhibit D, # 8 Exhibit E, # 9 Exhibit 2, # 10 Certificate of Service)(Silver, Daniel) Modified on 10/10/2024 (nms). (Entered: 10/09/2024) (0) |
| Oct 9, 2024 | 325 | [SEALED] Letter to The Honorable Richard G. Andrews, from Daniel M. Silver, Esq., regarding Novartis's request to amend (D.I. 324 ). (Attachments: # 1 Certificate of Service)(Silver, Daniel) Modified on 10/10/2024 (nms). (Entered: 10/09/2024) (0) |
| Oct 8, 2024 | 319 | ORAL ORDER: Inasmuch as Defendants Opening Brief (D.I. 315 in 22cv1395-RGA; D.I. 1560 in 20md2930-RGA) in support of their Daubert motion exceeds the page limits, it is STRUCK. Ordered by Judge Richard G. Andrews on 10/8/2024. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA(nms) (Entered: 10/08/2024) (0) |
| Oct 8, 2024 | 320 | ORAL ORDER: The Scheduling Orders filed on July 6, 2023 (D.I. 1097 and 1098 in 20-md-2930-RGA; D.I. 85 in 22-cv-1395-RGA; D.I. 19 in 23-cv-401-RGA) are now AMENDED to reflect as follows regarding paragraph 10, subsection b: "Absent an order of the Court upon showing of good cause, each side is limited to one twenty-page opening brief, one twenty-page answering brief, and one ten-page reply brief for all its Daubert motions". Ordered by Judge Richard G. Andrews on 10/8/2024. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA, 1:23-cv-00401-RGA(nms) (Entered: 10/08/2024) (0) |
| Oct 7, 2024 | 317 | ORAL ORDER: The Court has no objection to the timetable, but the Court does object to the excessive number of pages contemplated for Daubert briefing. The stipulation (D.I. 1556 in 20-md-02930-RGA: D.I. 311 in 22-cv-1395-RGA) is therefore DENIED. Ordered by Judge Richard G. Andrews on 10/7/2024. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA(nms) (Entered: 10/07/2024) (0) |
| Oct 7, 2024 | 318 | ORAL ORDER: The parties have advised that disputes have arisen requiring attention. The Court will hold a discovery conference on 10/21/2024, at 2:00 PM in Courtroom 6A. In preparation for this conference the parties shall follow the Discovery Matters and Disputes procedure as set forth in the Scheduling Order. Ordered by Judge Richard G. Andrews on 10/7/2024. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA(nms) Modified on 10/8/2024 (nms). (Entered: 10/07/2024) (0) |
| Oct 4, 2024 | 308 | ORDER SETTING BOND: In my judgment, MSN has a lot more to lose by an amount that is too low than Novartis has to lose by an amount that is too high. Thus, I adopt MSNs proposal. I will separately issue an order in the format suggested by the parties. (see 22cv1395-RGA, D.I. 299-1) (see Order for further details). Signed by Judge Richard G. Andrews on 10/4/2024. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-02053-RGA, 1:22-cv-01395-RGA(nms) (Entered: 10/04/2024) (2) |
| Oct 4, 2024 | 309 | ORDER REGARDING INJUNCTION BOND (see Order for further details). Signed by Judge Richard G. Andrews on 10/4/2024. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-02053-RGA, 1:22-cv-01395-RGA(nms) (Entered: 10/04/2024) (5) |
| Oct 4, 2024 | 310 | MOTION to Exclude the Trial Testimony of Experts Dr. Richard McCreery, Dr. Clare Strachan, and Dr. Jonathan Steed Under Fed. R. Evid. 702 and Daubert - filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Proposed Order, # 2 7.1.1. Certification)(Silver, Daniel) Modified on 10/7/2024 (nms). (Entered: 10/04/2024) (0) |
| Oct 4, 2024 | 311 | STIPULATION and Proposed Order to Extend Time - filed by Gerbera Therapeutics Inc., MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc., Nanjing Noratech Pharmaceutical Co., Limited, Novartis Pharmaceuticals Corporation. (Gattuso, Dominick) Modified on 10/7/2024 (nms). (Entered: 10/04/2024) (4) |
| Oct 4, 2024 | 312 | [SEALED] OPENING BRIEF in Support re 310 MOTION to Exclude the Trial Testimony of Defendants' Experts Dr. Richard McCreery, Dr. Clare Strachan, and Dr. Jonathan Steed Under Fed. R. Evid. 702 and Daubert filed by Novartis Pharmaceuticals Corporation.Answering Brief/Response due date per Local Rules is 10/18/2024. (Attachments: # 1 Certificate of Service)(Silver, Daniel) (Entered: 10/04/2024) (0) |
| Oct 4, 2024 | 313 | [SEALED] DECLARATION of Gregory J. Manas re 1555 MOTION to Exclude the Trial Testimony of Experts Dr. Richard McCreery, Dr. Clare Strachan, and Dr. Jonathan Steed Under Fed. R. Evid. 702 and Daubert, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibits 1-13, # 2 Certificate of Service)(Silver, Daniel) Modified on 10/7/2024 (nms). (Entered: 10/04/2024) (0) |
| Oct 4, 2024 | 314 | DAUBERT Motion to Exclude Testimony and Materials of Aeri Park, PH.D. - filed by Gerbera Therapeutics Inc., MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc., Nanjing Noratech Pharmaceutical Co., Limited. (Attachments: # 1 Proposed Order, # 2 7.1.1 Statement)(Gattuso, Dominick) Modified on 10/7/2024 (nms). (Entered: 10/04/2024) (0) |
| Oct 4, 2024 | 316 | [SEALED] DECLARATION of Don J. Mizerk to 314 DAUBERT Motion to Exclude Testimony and Materials of Aeri Park, PH.D., by Gerbera Therapeutics Inc., MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc., Nanjing Noratech Pharmaceutical Co., Limited. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Certificate of Service)(Gattuso, Dominick) Modified on 10/7/2024 (nms). (Entered: 10/04/2024) (0) |
| Oct 1, 2024 | 307 | NOTICE to Take Deposition of Carolyn J. Otten, Ph.D. on October 2, 2024 filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) (Entered: 10/01/2024) (2) |
| Sep 19, 2024 | 306 | REDACTED VERSION of 299 Letter, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Declaration, # 8 Declaration)(Joyce, Alexandra) Modified on 9/19/2024 (nms). (Entered: 09/19/2024) (0) |
| Sep 18, 2024 | 303 | NOTICE to Take Deposition of Hossein Ardehali, M.D., Ph.D. on September 26, 2024 filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) (Entered: 09/18/2024) (2) |
| Sep 18, 2024 | 304 | NOTICE to Take Deposition of Jeremy K. Cockcroft, Ph.D. on September 25, 2024 filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) (Entered: 09/18/2024) (2) |
| Sep 18, 2024 | 305 | NOTICE to Take Deposition of Clare Strachan, Ph.D. on September 24, 2024 filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) (Entered: 09/18/2024) (2) |
| Sep 17, 2024 | 302 | NOTICE OF SERVICE of Notice of Deposition of Adam J. Matzger, Ph.D. filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc..(Weinblatt, Richard) (Entered: 09/17/2024) (2) |
| Sep 16, 2024 | 300 | REDACTED VERSION of 287 Letter, by Gerbera Therapeutics Inc., Nanjing Noratech Pharmaceutical Co., Limited. (Attachments: # 1 Exhibit G, # 2 Exhibit H, # 3 Exhibit I)(Gattuso, Dominick) (Entered: 09/16/2024) (0) |
| Sep 16, 2024 | 301 | REDACTED VERSION of 290 Letter, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 9/16/2024 (nms). (Entered: 09/16/2024) (4) |
| Sep 13, 2024 | 296 | REDACTED VERSION of 287 Letter, by Gerbera Therapeutics Inc., Nanjing Noratech Pharmaceutical Co., Limited. (Attachments: # 1 Exhibit G, # 2 Exhibit H)(Gattuso, Dominick) (Entered: 09/13/2024) (0) |
| Sep 13, 2024 | 297 | NOTICE to Take Deposition of Richard L. McCreery, Ph.D. on September 18, 2024 filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) (Entered: 09/13/2024) (2) |
| Sep 13, 2024 | 298 | NOTICE to Take Deposition of Jonathan W. Steed, Ph.D. on September 17, 2024 filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) (Entered: 09/13/2024) (2) |
| Sep 13, 2024 | 299 | [SEALED] Joint Letter to The Honorable Richard G. Andrews, from Novartis and MSN, regarding bond pending appeal. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 McDuff Declaration, # 8 Chintapally Declaration, # 9 Certificate of Service) (Silver, Daniel) Modified on 9/16/2024 (nms). (Entered: 09/13/2024) (0) |
| Sep 12, 2024 | 294 | ORDER of USCA as to 240 Notice of Appeal (Federal Circuit) filed by Novartis Pharmaceuticals Corporation. Decision of USCA: Upon consideration of the parties' responses to this court's August 22, 2024 order, IT IS ORDERED THAT: Appellants are directed to file a bond in the district court in an amount, and subject to terms and conditions, deemed appropriate by the district court.. (nms) (Entered: 09/12/2024) (3) |
| Sep 12, 2024 | 295 | ORAL ORDER: A joint submission with a proposed order in follow up to The Federal Circuit's September 12, 2024, Order is due by the COB tomorrow (9/13/2024). To the extent the parties cannot agree, they should include arguments in support of their respective positions. Ordered by Judge Richard G. Andrews on 9/12/2024. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-02021-RGA, 1:19-cv-02053-RGA, 1:22-cv-01395-RGA(nms) (Entered: 09/12/2024) (0) |
| Sep 10, 2024 | 292 | MOTION for Pro Hac Vice Appearance of Attorney Gregory J. Manas and Carrie S. Park - filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certifications)(Silver, Daniel) Modified on 9/11/2024 (nms). (Entered: 09/10/2024) (0) |
| Sep 10, 2024 | 293 | Pro Hac Vice Fee - Credit Card Payment received for Gregory J. Manas and Carrie S. Park. ( re 292 MOTION for Pro Hac Vice Appearance of Attorney Gregory J. Manas and Carrie S. Park )( Payment of $ 100, receipt number ADEDC-4495461).(Silver, Daniel) (Entered: 09/10/2024) (0) |
| Sep 9, 2024 | 290 | [SEALED] Letter to The Honorable Richard G. Andrews, from Daniel M. Silver, Esq., regarding response to Defendants Gerbera and Noratech's supplemental letter for the September 9 Discovery Hearing. (Attachments: # 1 Certificate of Service)(Silver, Daniel) Modified on 9/9/2024 (nms). (Entered: 09/09/2024) (0) |
| Sep 9, 2024 | 291 | ORDER Granting (D.I. 289 in 22-cv-1395-RGA; D.I. 108 in 23-cv-401-RGA; D.I. 1530 in 20-md-2930-RGA) Unopposed Motion for Exemption of Persons from the District of Delaware's May 17, 2024 Standing Order on Personal Devices. Signed by Judge Richard G. Andrews on 9/9/2024. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA, 1:23-cv-00401-RGA(nms) (Entered: 09/09/2024) (2) |
| Sep 6, 2024 | 287 | [SEALED] Letter to The Honorable Richard G. Andrews, from Dominick T. Gattuso, Esq., regarding newly obtained, supplemental information relevant to September 9 discovery hearing. (Attachments: # 1 Exhibit G, # 2 Exhibit H, # 3 Exhibit I, # 4 Certificate of Service)(Gattuso, Dominick) Modified on 9/6/2024 (nms). (Entered: 09/06/2024) (0) |
| Sep 6, 2024 | 288 | REDACTED VERSION of 285 Letter, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 9/6/2024 (nms). (Entered: 09/06/2024) (24) |
| Sep 6, 2024 | 289 | Unopposed Motion for Exemption of Persons from the District of Delaware's May 17, 2024 Standing Order on Personal Devices - filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Proposed Order)(Silver, Daniel) Modified on 9/9/2024 (nms). (Entered: 09/06/2024) (0) |
| Sep 4, 2024 | 286 | REDACTED VERSION of 281 Letter, by Gerbera Therapeutics Inc., Nanjing Noratech Pharmaceutical Co., Limited. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F)(Gattuso, Dominick) (Entered: 09/04/2024) (0) |
| Aug 30, 2024 | 285 | [SEALED] Letter to The Honorable Richard G. Andrews, from Daniel M. Silver, Esq., regarding response to discovery dispute. (Attachments: # 1 Exhibits 1-4, # 2 Proposed Order, # 3 Certificate of Service)(Silver, Daniel) Modified on 8/30/2024 (nms). (Entered: 08/30/2024) (0) |
| Aug 29, 2024 | 283 | MOTION for Pro Hac Vice Appearance of Attorney Elizabeth Bernard - filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc.. (Weinblatt, Richard) (Entered: 08/29/2024) (5) |
| Aug 29, 2024 | 284 | Pro Hac Vice Fee - Credit Card Payment received for Elizabeth Bernard. ( re 283 MOTION for Pro Hac Vice Appearance of Attorney Elizabeth Bernard )( Payment of $ 50, receipt number ADEDC-4488086).(Weinblatt, Richard) (Entered: 08/29/2024) (0) |
| Aug 28, 2024 | 280 | REDACTED VERSION of 237 MOTION to Strike Portions of Declaration of Adam J. Matzger, Ph.D., by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Proposed Order)(Weinblatt, Richard) Modified on 8/28/2024 (nms). (Entered: 08/28/2024) (0) |
| Aug 28, 2024 | 281 | [SEALED] Letter to The Honorable Richard G. Andrews, from Dominick T. Gattuso, regarding discovery dispute. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Certificate of Service)(Gattuso, Dominick) Modified on 8/28/2024 (nms). (Entered: 08/28/2024) (0) |
| Aug 28, 2024 | 282 | PROPOSED Order Granting Nanjing Noratech Pharmaceutical Co., Limited's Requested Relief Related to Discovery Disputes (D.I. 281), by Gerbera Therapeutics Inc., Nanjing Noratech Pharmaceutical Co., Limited. (Gattuso, Dominick) Modified on 8/28/2024 (nms). (Entered: 08/28/2024) (2) |
| Aug 27, 2024 | 277 | REDACTED VERSION of 217 Appendix, by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc.. (Attachments: # 1 part 2, # 2 part 3, # 3 part 4)(Weinblatt, Richard) Modified on 8/28/2024 (nms). (Entered: 08/27/2024) (0) |
| Aug 27, 2024 | 278 | REDACTED VERSION of 218 Appendix, by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc.. (Attachments: # 1 part 2)(Weinblatt, Richard) Modified on 8/28/2024 (nms). (Entered: 08/27/2024) (0) |
| Aug 27, 2024 | 279 | REDACTED VERSION of 232 Declaration of Dr. Jonathan W. Steed, by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc.. (Weinblatt, Richard) Modified on 8/28/2024 (nms). (Entered: 08/27/2024) (30) |
| Aug 23, 2024 | 276 | ORAL ORDER: The parties have advised that a dispute has arisen requiring attention. The Court will hold a discovery conference on 9/9/2024, at 2:00 PM in Courtroom 6A. In preparation for this conference the parties shall follow the Discovery Matters and Disputes procedure as set forth in the Scheduling Order.. Ordered by Judge Richard G. Andrews on 8/23/2024. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA, 1:23-cv-00401-RGA(nms) (Entered: 08/23/2024) (0) |
| Aug 21, 2024 | 275 | ORAL ORDER: The redacted filings (D.I. 260 ; D.I. 268 ; D.I. 269 ) are REJECTED because parts of them are redacted in entirety. Absent a compelling reason, supported by a statement under oath by a party, redactions in their entirety are impermissible; redactions must be done so as to redact the least possible amount of the materials submitted. Failure to make a good faith attempt at such redactions may result in sanctions, the most common of which would be simply unsealing the entire filing. Redacting in its entirety a document, or parts of it, that contains publicly available materials is prima facie evidence of bad faith. Revised redacted filing are DUE within five business days. Ordered by Judge Richard G. Andrews on 8/21/2024. (nms) Modified on 8/28/2024 (nms). (Entered: 08/21/2024) (0) |
| Aug 20, 2024 | 254 | NOTICE of of Lodging by Gerbera Therapeutics Inc., Nanjing Noratech Pharmaceutical Co., Limited (Attachments: # 1 Exhibit 1)(Gattuso, Dominick) (Entered: 08/20/2024) (0) |
| Aug 20, 2024 | 255 | REDACTED VERSION of 242 Notice of Lodging of Demonstrative Slides from August 9, 2024 Preliminary Injunction Hearing, by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc.. (Attachments: # 1 Exhibit 1)(Weinblatt, Richard) Modified on 8/20/2024 (nms). (Entered: 08/20/2024) (0) |
| Aug 20, 2024 | 256 | REDACTED VERSION of 227 Answering Brief in Opposition, by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc.. (Weinblatt, Richard) Modified on 8/20/2024 (nms). (Entered: 08/20/2024) (25) |
| Aug 20, 2024 | 257 | REDACTED VERSION of 229 Declaration of DeForest McDuff, by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc.. (Weinblatt, Richard) Modified on 8/20/2024 (nms). (Entered: 08/20/2024) (28) |
| Aug 20, 2024 | 258 | REDACTED VERSION of 231 Declaration of of Bharat Reddy Chintapally, by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc.. (Weinblatt, Richard) Modified on 8/20/2024 (nms). (Entered: 08/20/2024) (7) |
| Aug 20, 2024 | 259 | REDACTED VERSION of 230 Declaration of of Dr. Richard L. McCreery, Ph.D., by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc.. (Attachments: # 1 Exhibits 2050-2060)(Weinblatt, Richard) Modified on 8/20/2024 (nms). (Entered: 08/20/2024) (0) |
| Aug 20, 2024 | 260 | REDACTED VERSION of 232 Declaration of Dr. Jonathan W. Steed, by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc.. (Weinblatt, Richard) Modified on 8/20/2024 (nms). (Entered: 08/20/2024) (30) |
| Aug 20, 2024 | 261 | REDACTED VERSION of 233 Appendix, Volume 1 of 3, by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc.. (Attachments: # 1 Exhibits 2001-2011, # 2 Exhibits 2012-2014, # 3 Exhibits 2015-2020)(Weinblatt, Richard) Modified on 8/20/2024 (nms). (Entered: 08/20/2024) (0) |
| Aug 20, 2024 | 262 | REDACTED VERSION of 234 Appendix, Volume 2 of 3, by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc.. (Attachments: # 1 Exhibits 2021-2025, # 2 Exhibits 2026-2029, # 3 Exhibits 2030-2033)(Weinblatt, Richard) Modified on 8/20/2024 (nms). (Entered: 08/20/2024) (0) |
| Aug 20, 2024 | 263 | REDACTED VERSION of 235 Appendix, Volume 3 of 3, by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc.. (Attachments: # 1 Exhibits 2034-2035, # 2 Exhibits 2036-2044, # 3 Exhibits 2045-2049)(Weinblatt, Richard) Modified on 8/20/2024 (nms). (Entered: 08/20/2024) (0) |
| Aug 20, 2024 | 264 | REDACTED VERSION of 213 MOTION for Preliminary Injunction against MSN , by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 8/21/2024 (nms). (Entered: 08/20/2024) (6) |
| Aug 20, 2024 | 265 | REDACTED VERSION of 214 Opening Brief in Support, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 8/21/2024 (nms). (Entered: 08/20/2024) (26) |
| Aug 20, 2024 | 266 | REDACTED VERSION of 215 Appendix, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Part 2, # 2 Part 3, # 3 Part 4)(Joyce, Alexandra) Modified on 8/21/2024 (nms). (Entered: 08/20/2024) (0) |
| Aug 20, 2024 | 267 | REDACTED VERSION of 216 Appendix, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Part 2, # 2 Part 3)(Joyce, Alexandra) Modified on 8/21/2024 (nms). (Entered: 08/20/2024) (0) |
| Aug 20, 2024 | 268 | REDACTED VERSION of 217 Appendix, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Part 2, # 2 Part 3)(Joyce, Alexandra) Modified on 8/21/2024 (nms). (Entered: 08/20/2024) (0) |
| Aug 20, 2024 | 269 | REDACTED VERSION of 218 Appendix, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Part 2)(Joyce, Alexandra) Modified on 8/21/2024 (nms). (Entered: 08/20/2024) (0) |
| Aug 20, 2024 | 270 | REDACTED VERSION of 219 Declaration, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 8/21/2024 (nms). (Entered: 08/20/2024) (30) |
| Aug 20, 2024 | 271 | DECLARATION of Brian Robinson in support of 270 Redacted Document, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 8/21/2024 (nms). (Entered: 08/20/2024) (6) |
| Aug 20, 2024 | 272 | REDACTED VERSION of 220 Declaration, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 8/21/2024 (nms). (Entered: 08/20/2024) (30) |
| Aug 20, 2024 | 273 | REDACTED VERSION of 221 Declaration, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 8/21/2024 (nms). (Entered: 08/20/2024) (30) |
| Aug 20, 2024 | 274 | REDACTED VERSION of 222 Declaration, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 8/21/2024 (nms). (Entered: 08/20/2024) (30) |
| Aug 19, 2024 | 253 | REDACTED VERSION of 241 Notice, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 8/19/2024 (nms). (Entered: 08/19/2024) (28) |
| Aug 16, 2024 | 252 | NOTICE of Lodging of Demonstrative Slides from March 12, 2024 Claim Construction Hearing, by Novartis Pharmaceuticals Corporation, (Attachments: # 1 Exhibit 1)(Silver, Daniel) Modified on 8/16/2024 (nms). (Entered: 08/16/2024) (0) |
| Aug 15, 2024 | 248 | ORDER of USCA as to 240 Notice of Appeal (Federal Circuit), filed by Novartis Pharmaceuticals Corporation. Decision of USCA: MSN is directed to respond to Novartiss motion no later than August 16, 2024, and any reply is due no later than August 19, 2024. MSN is temporarily enjoined from commercial marketing and sale of their generic version of Entresto while the court considers the Rule 8 motion. (nms) (Entered: 08/15/2024) (2) |
| Aug 15, 2024 | 249 | NOTICE OF SERVICE of (1) Reply Expert Report of Adam J. Matzger, Ph.D. on Infringement of U.S. Patent No. 11,096,918 by MSN Pharmaceuticals Inc., MSN Laboratories Private Limited, and MSN Life Sciences Private Limited, and (2) Reply Expert Report of Aeri Park, Ph.D. on U.S. Patent No. 11,096,918 for MSN Pharmaceuticals Inc., MSN Laboratories Private Limited, and MSN Life Sciences Private Limited filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 08/15/2024) (3) |
| Aug 15, 2024 | 250 | NOTICE OF SERVICE of (1) Reply Expert Report of Adam J. Matzger, Ph.D. on Infringement of U.S. Patent No. 11,096,918 by Nanjing Noratech Pharmaceutical Co., Limited and Gerbera Therapeutics, Inc., and (2) Reply Expert Report of Aeri Park, Ph.D. on U.S. Patent No. 11,096,918 for Nanjing Noratech Pharmaceutical Co., Limited and Gerbera Therapeutics, Inc. filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 08/15/2024) (2) |
| Aug 15, 2024 | 251 | REDACTED VERSION of 211 Letter, by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc.. (Weinblatt, Richard) Modified on 8/15/2024 (nms). (Entered: 08/15/2024) (6) |
| Aug 14, 2024 | 247 | REDACTED VERSION of 210 Letter, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 8/14/2024 (nms). (Entered: 08/14/2024) (30) |
| Aug 13, 2024 | 242 | [SEALED] NOTICE of of Lodging of Demonstrative Slides from August 9, 2024 Preliminary Injunction Hearing by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc. (Attachments: # 1 Exhibit 1)(Weinblatt, Richard) (Entered: 08/13/2024) (0) |
| Aug 13, 2024 | 243 | NOTICE of Docketing Record on Appeal from USCA for the Federal Circuit re 240 Notice of Appeal (Federal Circuit) filed by Novartis Pharmaceuticals Corporation. USCA Case Number 2024-2211 (nms) (Entered: 08/13/2024) (4) |
| Aug 13, 2024 | 244 | NOTICE of Docketing Record on Appeal from USCA for the Federal Circuit re 243 USCA Notice of Docketing ROA. USCA Case Number 2024-2212. (nms) (Entered: 08/13/2024) (4) |
| Aug 13, 2024 | 245 | NOTICE OF SERVICE of Reply Expert Report of Dr. Jonathan W. Steed Regarding Invalidity of United States Patent No. 11,096,918 filed by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc..(Weinblatt, Richard) (Entered: 08/13/2024) (2) |
| Aug 13, 2024 | 246 | Official Transcript of Oral Argument held on 08/09/24 before Judge Richard G. Andrews. Court Reporter/Transcriber Heather M. Triozzi,Email: Heather_Triozzi@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 9/3/2024. Redacted Transcript Deadline set for 9/13/2024. Release of Transcript Restriction set for 11/12/2024. (Triozzi, Heather) (Entered: 08/13/2024) (109) |
| Aug 12, 2024 | 239 | MEMORANDUM ORDER: Novartis's motion for preliminary injunction (D.I. 1422 in 20-md-2930-RGA; D.I. 213 in 22-cv-1395-RGA) is DENIED. MSN's motion to strike (D.I. 237 in 22cv1395-RGA; D.I. 1454 in 20md2930-RGA) is DISMISSED AS MOOT. I will grant Novartis' s request for a stay (id) to allow Novartis to seek injunctive relief from the Federal Circuit. I expect Novartis to appeal this Memorandum Order by filing a notice of appeal today. I further expect Novartis to file emergency motions in the Court of Appeals as soon as possible. With that understanding, Novartis and MSN are hereby ordered to maintain the status quo for 72 hours from the issuance of this Memorandum Order. I expect the Court of Appeals is in the best position to decide whether to continue the stay, and, if it does, for how long. Signed by Judge Richard G. Andrews on 8/12/2024. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA(nms) (Entered: 08/12/2024) (11) |
| Aug 12, 2024 | 240 | NOTICE OF APPEAL to the Federal Circuit of 239 Memorandum and Order. Appeal filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 8/13/2024 (nms). (Entered: 08/12/2024) (2) |
| Aug 12, 2024 | 241 | [SEALED] NOTICE of Lodging of Demonstrative Slides from August 9, 2024 Preliminary Injunction Hearing by Novartis Pharmaceuticals Corporation, (Attachments: # 1 Exhibit 1 , # 2 Certificate of Service)(Silver, Daniel) Modified on 8/13/2024 (nms). (Entered: 08/12/2024) (0) |
| Aug 9, 2024 | 238 | ORDER: As stated at the August 9, 2024 hearing, Plaintiff Novartis Pharmaceuticals Corporation and Defendants MSN Pharmaceuticals Inc., MSN Laboratories Private Limited, and MSN Life Sciences Private Limited are ordered to maintain the status quo until the Court issues its decisions on the pending motions seeking injunctive relief. (MDL No. 20-2930, D.I. 1422,1423). Signed by Judge Richard G. Andrews on 8/9/2024. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-02053-RGA, 1:22-cv-01395-RGA(nms) (Entered: 08/09/2024) (2) |
| Aug 8, 2024 | 237 | [SEALED] MOTION to Strike Portions of Declaration of Adam J. Matzger, Ph.D. (D.I. 221) - filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Proposed Order)(Weinblatt, Richard) Modified on 8/9/2024 (nms). (Entered: 08/08/2024) (0) |
| Aug 7, 2024 | 232 | [SEALED] DECLARATION of Dr. Jonathan W. Steed re 227 Answering Brief, by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc.. (Weinblatt, Richard) Modified on 8/7/2024 (nms). (Entered: 08/07/2024) (0) |
| Aug 7, 2024 | 233 | [SEALED] APPENDIX, Volume 1 of 3 to 232 Declaration, by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc.. (Attachments: # 1 Exhibits 2001-2011, # 2 Exhibits 2012-2014, # 3 Exhibits 2015-2020)(Weinblatt, Richard) Modified on 8/7/2024 (nms). (Entered: 08/07/2024) (0) |
| Aug 7, 2024 | 234 | [SEALED] APPENDIX, Volume 2 of 3 to 232 Declaration, by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc.. (Attachments: # 1 Exhibits 2021-2025, # 2 Exhibits 2026-2029, # 3 Exhibits 2030-2033)(Weinblatt, Richard) Modified on 8/7/2024 (nms). (Entered: 08/07/2024) (0) |
| Aug 7, 2024 | 235 | [SEALED] APPENDIX, Volume 3 of 3 to 232 Declaration, by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc.. (Attachments: # 1 Exhibits 2034-2035, # 2 Exhibits 2036-2044, # 3 Exhibits 2045-2049)(Weinblatt, Richard) Modified on 8/7/2024 (nms). (Entered: 08/07/2024) (0) |
| Aug 7, 2024 | 236 | STIPULATION TO EXTEND TIME the deadline to submit a public, redacted version of the Letter to the Honorable Richard G. Andrews from Daniel M. Silver, Esq. on Behalf of Novartis (D.I. 1417 in C.A. No. 20-2930) to August 14, 2024 - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 08/07/2024) (3) |
| Aug 6, 2024 | 223 | Joint Motion for Exemption of Persons from the District of Delaware's May 17, 2024 Standing Order on Personal Devices - filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Proposed Order)(Joyce, Alexandra) Modified on 8/7/2024 (nms). (Entered: 08/06/2024) (0) |
| Aug 6, 2024 | 224 | ORDER: The Joint Motion for Exemption of Persons from the District of Delaware's May 17, 2024 Standing Order on Personal Devises (D.I. 1436 in 20-md-2930-RGA; D.I. 425 in 19-cv-2053-RGA; D.I. 223 in 22-cv-1395-RGA) is Granted in Part and Denied in Part. The application as it applies to the client representatives is Denied. Signed by Judge Richard G. Andrews on 8/6/2024. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-02053-RGA, 1:22-cv-01395-RGA(nms) (Entered: 08/06/2024) (2) |
| Aug 6, 2024 | 225 | STIPULATION and Proposed Order to Extend Time - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 8/6/2024 (nms). (Entered: 08/06/2024) (3) |
| Aug 6, 2024 | 226 | STIPULATION and Proposed Order to Extend Time to Serve Reply Expert Reports to August 13, 2024 - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 8/6/2024 (nms). (Entered: 08/06/2024) (3) |
| Aug 6, 2024 | 227 | [SEALED] ANSWERING BRIEF in Opposition re 213 MOTION for Preliminary Injunction against MSN filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc..Reply Brief due date per Local Rules is 8/13/2024. (Weinblatt, Richard) (Entered: 08/06/2024) (0) |
| Aug 6, 2024 | 229 | [SEALED] DECLARATION of DeForest McDuff re 227 Answering Brief in Opposition, by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc.. (Weinblatt, Richard) Modified on 8/7/2024 (nms). (Entered: 08/06/2024) (0) |
| Aug 6, 2024 | 230 | [SEALED] DECLARATION of Dr. Richard L. McCreery, Ph.D. re 227 Answering Brief in Opposition, by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc.. (Attachments: # 1 Exhibits 2050-2060)(Weinblatt, Richard) Modified on 8/7/2024 (nms). (Entered: 08/06/2024) (0) |
| Aug 6, 2024 | 231 | [SEALED] DECLARATION of Bharat Reddy Chintapally re 227 Answering Brief in Opposition, by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc.. (Weinblatt, Richard) Modified on 8/7/2024 (nms). (Entered: 08/06/2024) (0) |
| Aug 2, 2024 | 213 | [SEALED] MOTION for Preliminary Injunction against MSN - filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Proposed Order, # 2 7.1.1 Certification, # 3 Certificate of Service)(Silver, Daniel) Modified on 8/4/2024 (nms). Modified on 8/4/2024 (nms). (Entered: 08/02/2024) (0) |
| Aug 2, 2024 | 214 | [SEALED] OPENING BRIEF in Support re 213 MOTION for Preliminary Injunction against MSN, filed by Novartis Pharmaceuticals Corporation. Answering Brief/Response due date per Local Rules is 8/16/2024. (Attachments: # 1 Certificate of Service)(Silver, Daniel) Modified on 8/4/2024 (nms). (Entered: 08/02/2024) (0) |
| Aug 2, 2024 | 215 | [SEALED] APPENDIX, Volume 1 of 4 to 214 Opening Brief in Support, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibits 1001-1009, # 2 Exhibits 1010-1017, # 3 Exhibits 1018-1025, # 4 Exhibits 1026-1033, # 5 Certificate of Service)(Silver, Daniel) Modified on 8/4/2024 (nms). (Entered: 08/02/2024) (0) |
| Aug 2, 2024 | 216 | [SEALED] APPENDIX, Volume 2 of 4 to 214 Opening Brief in Support, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibits 1034-1044, # 2 Exhibits 1045-1057, # 3 Exhibits 1058-1071, # 4 Certificate of Service)(Silver, Daniel) Modified on 8/4/2024 (nms). (Entered: 08/02/2024) (0) |
| Aug 2, 2024 | 217 | [SEALED] APPENDIX, Volume 3 of 4 to 214 Opening Brief in Support, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibits 1501-1506, # 2 Exhibits 1507-1508, # 3 Exhibits 1509-1510, # 4 Exhibits 1511-1517, # 5 Exhibits 1518-1521, # 6 Exhibits 1522-1532, # 7 Exhibits 1533-1538, # 8 Certificate of Service)(Silver, Daniel) Modified on 8/4/2024 (nms). (Entered: 08/02/2024) (0) |
| Aug 2, 2024 | 218 | [SEALED] APPENDIX, Volume 4 of 4 to 214 Opening Brief in Support, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibits 1539-1542, # 2 Exhibits 1543-1548, # 3 Exhibits 1549-1551, # 4 Certificate of Service)(Silver, Daniel) Modified on 8/4/2024 (nms). (Entered: 08/02/2024) (0) |
| Aug 2, 2024 | 219 | [SEALED] DECLARATION of Christopher A. Vellturo, Ph.D. re 214 Opening Brief in Support, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibits 1-9, # 2 Exhibit 10 (Part 1), # 3 Exhibit 10 (Part 2), # 4 Exhibits 11-17, # 5 Certificate of Service)(Silver, Daniel) Modified on 8/4/2024 (nms). (Entered: 08/02/2024) (0) |
| Aug 2, 2024 | 220 | [SEALED] DECLARATION of Aeri Park, PH.D. re 214 Opening Brief in Support, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certificate of Service)(Silver, Daniel) Modified on 8/4/2024 (nms). (Entered: 08/02/2024) (0) |
| Aug 2, 2024 | 221 | [SEALED] DECLARATION of Adam J. Matzger, Ph.D. re 214 ] Opening Brief in Support, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certificate of Service)(Silver, Daniel) Modified on 8/4/2024 (nms). (Entered: 08/02/2024) (0) |
| Aug 2, 2024 | 222 | [SEALED] DECLARATION of Bernhardt L. Trout, Ph.D. re 214 Opening Brief in Support, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certificate of Service)(Silver, Daniel) Modified on 8/4/2024 (nms). (Entered: 08/02/2024) (0) |
| Aug 1, 2024 | 212 | ORAL ORDER: The Court declines to extend the current notice requirements (see D.I. 1417 and D.I. 1418 in 20md2930-RGA). The Court is relatively certain that Novartis and MSN are all prepared to go on emergency injunctive relief. If Novartis wants to seek such relief, Novartis should file the appropriate papers by the COB August 2, 2024, and MSN can file a brief and other papers in opposition by the COB August 6, 2024, and the Court will hold a hearing on the motion(s) on August 9, 2024, at 9 a.m.. Ordered by Judge Richard G. Andrews on 8/1/2024. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA, 1:23-cv-00401-RGA(nms) (Entered: 08/01/2024) (0) |
| Jul 31, 2024 | 210 | [SEALED] Letter to The Honorable Richard G. Andrews, from Daniel M. Silver, on behalf of Novartis regarding request for extension of the Court's June 20, 2023 Order. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Certificate of Service)(Silver, Daniel) Modified on 8/1/2024 (nms). (Entered: 07/31/2024) (0) |
| Jul 31, 2024 | 211 | [SEALED] Letter to The Honorable Richard G. Andrews, from Defendants, regarding expiration of Order regarding generic launch. (Weinblatt, Richard) Modified on 8/1/2024 (nms). (Entered: 07/31/2024) (0) |
| Jul 29, 2024 | 209 | Letter to The Honorable Richard G. Andrews, from Dominick T. Gattuso, regarding response to Oral Order (D.I. 208 ). (Attachments: # 1 Declaration, # 2 Exhibits 1-13)(Gattuso, Dominick) Modified on 7/29/2024 (nms). (Entered: 07/29/2024) (0) |
| Jul 22, 2024 | 208 | ORAL ORDER: The redacted filing (D.I. 207 ) is REJECTED because parts of it are redacted in its entirety. Absent a compelling reason, supported by a statement under oath by a party, redactions in their entirety are impermissible; redactions must be done so as to redact the least possible amount of the materials submitted. Failure to make a good faith attempt at such redactions may result in sanctions, the most common of which would be simply unsealing the entire filing. Redacting in its entirety a document, or parts of it, that contains publicly available materials is prima facie evidence of bad faith. A revised redacted filing is DUE within five business days. Ordered by Judge Richard G. Andrews on 7/22/2024. (nms) (Entered: 07/22/2024) (0) |
| Jul 12, 2024 | 206 | REDACTED VERSION of 201 Letter, by Gerbera Therapeutics Inc., Nanjing Noratech Pharmaceutical Co., Limited. (Attachments: # 1 Exhibit A)(Gattuso, Dominick) Modified on 7/12/2024 (nms). (Entered: 07/12/2024) (0) |
| Jul 12, 2024 | 207 | REDACTED VERSION of 200 Letter, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 7/12/2024 (nms). (Entered: 07/12/2024) (30) |
| Jul 5, 2024 | 204 | NOTICE OF SERVICE of (1) Responsive Expert Report of Bernhardt L. Trout, Ph.D. on the Validity of U.S. Patent No. 11,096,918, and (2) Responsive Expert Report of Aeri Park, Ph.D. on U.S. Patent No. 11,096,918 filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 07/05/2024) (2) |
| Jul 5, 2024 | 205 | STIPULATION and Proposed Order to Extend Time to file public versions of D.I. 1395 and D.I. 1397 to July 12, 2024 - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 7/8/2024 (nms). (Entered: 07/05/2024) (2) |
| Jul 3, 2024 | 202 | NOTICE OF SERVICE of (i) the Rebuttal Expert Report of Dr. Richard L. McCreery, Ph.D. on behalf of Nanjing Noratech Pharmaceutical Co., Limited and Gerbera Therapeutics, Inc. (with Exs. A-C); (ii) the Responsive Expert Report of Dr. Clare Strachan, Ph.D. on behalf of Nanjing Noratech Pharmaceutical Co., Limited and Gerbera Therapeutics, Inc. (with Appendix I and Exs. A-C); and, (iii) the Rebuttal Expert Report of Jeremy Karl Cockroft, Ph.D. on behalf of Nanjing Noratech Pharmaceutical Co., Limited and Gerbera Therapeutics, Inc. (with Exs. A-C) filed by Novartis Pharmaceuticals Corporation, Nanjing Noratech Pharmaceutical Co., Limited.(Gattuso, Dominick) (Entered: 07/03/2024) (2) |
| Jul 3, 2024 | 203 | NOTICE OF SERVICE of Responsive Expert Report of Dr. Jonathan W. Steed Regarding MSNs Non-Infringement of United States Patent No. 11,096,918 [HIGHLY CONFIDENTIAL OUTSIDE COUNSEL EYES ONLY] filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc..(Weinblatt, Richard) (Entered: 07/03/2024) (2) |
| Jul 1, 2024 | 201 | [SEALED] Letter to The Honorable Richard G. Andrews, from Dominick T. Gattuso, regarding discovery dispute. (Attachments: # 1 Exhibit A)(Gattuso, Dominick) Modified on 7/1/2024 (nms). (Entered: 07/01/2024) (0) |
| Jun 27, 2024 | 200 | [SEALED] Letter to The Honorable Richard G. Andrews, from Daniel M. Silver, Esq., regarding discovery dispute. (Attachments: # 1 Exhibits 1-13, # 2 Proposed Order, # 3 Certificate of Service)(Silver, Daniel) Modified on 6/27/2024 (nms). (Entered: 06/27/2024) (0) |
| Jun 20, 2024 | 199 | NOTICE OF SERVICE of (1) Second Supplemental Opening Expert Report of Adam J. Matzger, Ph.D. on Infringement of U.S. Patent No. 11,096,918 by Nanjing Noratech Pharmaceutical Co., Limited and Gerbera Therapeutics, Inc., and (2) Second Supplemental Expert Report of Aeri Park, Ph.D. on U.S. Patent No. 11,096,918 filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) (Entered: 06/20/2024) (3) |
| Jun 13, 2024 | 198 | NOTICE OF SERVICE of (1) Supplemental Opening Expert Report of Adam J. Matzger, Ph.D. on Infringement of U.S. Patent No. 11,096,918 by Defendants and (2) Supplemental Expert Report of Aeri Park, Ph.D. on U.S. Patent No. 11,096,918 filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 06/13/2024) (4) |
| Jun 12, 2024 | 196 | ORAL ORDER: The parties have advised that a dispute has arisen requiring attention. The Court will hold a discovery conference on 7/9/2024, at 10:00 AM in Courtroom 6A. In preparation for this conference the parties shall follow the Discovery Matters and Disputes procedure as set forth in the Scheduling Order. Ordered by Judge Richard G. Andrews on 6/12/2024. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA, 1:23-cv-00401-RGA(lah) (Entered: 06/12/2024) (0) |
| Jun 12, 2024 | 197 | NOTICE OF SERVICE of Supplemental Opening Expert Report of Dr. Jonath W. Steed Regarding the Invalidity of United States Patent No. 11,096,918 [HIGHLY CONFIDENTIAL OUTSIDE COUNSEL EYES ONLY] filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc..(Weinblatt, Richard) (Entered: 06/12/2024) (2) |
| Jun 10, 2024 | 195 | STIPULATION and Proposed Order to Extend Time for discovery - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 6/10/2024 (nms). (Entered: 06/10/2024) (4) |
| May 31, 2024 | 194 | MEMORANDUM OPINION regarding claim construction of one term in U.S. Patent No. 11,096,918 (see Memorandum Opinion for further details). Signed by Judge Richard G. Andrews on 5/31/2024. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA(nms) (Entered: 05/31/2024) (10) |
| May 29, 2024 | 192 | STIPULATION and [Proposed] Order to Extend Deadlines for Responsive and Reply Expert Reports by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 05/29/2024) (4) |
| May 29, 2024 | 193 | SO ORDERED Granting (D.I. 1372 in 20-md-2930-RGA; D.I. 192 in 22-cv-1395-RGA) Stipulation and Proposed Order to Extend Deadlines for Responsive and Reply Expert Reports. Signed by Judge Richard G. Andrews on 5/29/2024. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA(nms) (Entered: 05/29/2024) (4) |
| May 24, 2024 | 191 | NOTICE OF SERVICE of (1) Supplemental Opening Expert Report of Adam J. Matzger, Ph.D. on Infringement of U.S. Patent No. 11,096,918 by MSN Pharmaceuticals Inc., MSN Laboratories Private Limited, and MSN Life Sciences Private Limited; and (2) Supplemental Expert Report of Aeri Park, Ph.D. on U.S. Patent No. 11,096,918 filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 05/24/2024) (3) |
| May 15, 2024 | 190 | REDACTED VERSION of 185 Letter, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 5/15/2024 (nms). (Entered: 05/15/2024) (30) |
| May 13, 2024 | 188 | NOTICE OF SERVICE of (1) Opening Expert Report of Adam J. Matzger, Ph.D. on Infringement of U.S. Patent No. 11,096,918 by Nanjing Noratech Pharmaceutical Co., Limited and Gerbera Therapeutics, Inc., and (2) Expert Report of Aeri Park, Ph.D. on U.S. Patent No. 11,096,918 filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 05/13/2024) (3) |
| May 13, 2024 | 189 | ORAL ORDER: The Court has considered the parties discovery dispute letters. (No. 20-2930, D.I. 1354, 1358). MSNs request to compel production of testing records is DENIED. The conference scheduled for 5/15/2024 is CANCELED. Defendant has not waived the work product privilege that protects the relevant testing data from discovery. Novartis decision to withdraw infringement allegations in an earlier case does not qualify as using privilege as a sword. In addition, the testing records appear to be shielded from discovery by the stipulated protective order. (See 20-2930, D.I. 80 50). Ordered by Judge Richard G. Andrews on 5/13/2024. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA(nms) (Entered: 05/13/2024) (0) |
| May 10, 2024 | 186 | NOTICE requesting Clerk to remove Femi L. Masha of Husch Blackwell LLP as co-counsel. Reason for request: No Longer with Firm. (Gattuso, Dominick) (Entered: 05/10/2024) (2) |
| May 10, 2024 | 187 | NOTICE OF SERVICE of (1) Opening Expert Report of Dr. Jonathan W. Steed Regarding the Invalidity of United States Patent No. 11,096,918 [HIGHLY CONFIDENTIAL OUTSIDE COUNSEL EYES ONLY UNDER D. DEL. L. R. 26.2] and (2) Opening Expert Report of Dr. Hossein Ardehali Regarding the Invalidity of United States Patent No. 11,096,918 [HIGHLY CONFIDENTIAL OUTSIDE COUNSEL EYES ONLY UNDER D. DEL. L. R. 26.2] filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 05/10/2024) (2) |
| May 8, 2024 | 185 | [SEALED] Letter to The Honorable Richard G. Andrews, from Daniel M. Silver, Esq., regarding response to MSN's May 6, 2024 discovery dispute letter. (Attachments: # 1 Exhibits A-E, # 2 Proposed Order, # 3 Certificate of Service)(Silver, Daniel) Modified on 5/8/2024 (nms). (Entered: 05/08/2024) (0) |
| May 7, 2024 | 184 | PROPOSED Order re 183 Letter, by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc.. (Weinblatt, Richard) Modified on 5/8/2024 (nms). (Entered: 05/07/2024) (1) |
| May 6, 2024 | 183 | Letter to The Honorable Richard G. Andrews, from Richard C. Weinblatt, regarding discovery dispute. (Weinblatt, Richard) Modified on 5/7/2024 (nms). (Entered: 05/06/2024) (5) |
| Apr 30, 2024 | 182 | Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Gerbera Therapeutics Inc.. (Gattuso, Dominick) (Entered: 04/30/2024) (2) |
| Apr 26, 2024 | 180 | STIPULATION and [Proposed] Order Joining Gerbera Therapeutics, Inc. by Novartis Pharmaceuticals Corporation. (Silver, Daniel) (Entered: 04/26/2024) (7) |
| Apr 26, 2024 | 181 | SO ORDERED Granting (D.I. 180 in 22-cv-01395-RGA; D.I. 1339 in 20-md-02930-RGA; D.I. 68 in 23-cv-401-RGA) Stipulation and Proposed Order Joining Gerbera Therapeutics, Inc.. Signed by Judge Richard G. Andrews on 4/26/2024. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA, 1:23-cv-00401-RGA(nms) (Entered: 04/26/2024) (7) |
| Apr 16, 2024 | 179 | ORAL ORDER: The parties have advised that a dispute has arisen requiring attention. The Court will hold a discovery conference on 5/15/2024, at 2:00 PM in Courtroom 6A. In preparation for this conference the parties shall follow the Discovery Matters and Disputes procedure as set forth in the Scheduling Order. Ordered by Judge Richard G. Andrews on 4/16/2024. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA(nms) (Entered: 04/16/2024) (0) |
| Apr 15, 2024 | 178 | ORAL ORDER: The parties have advised that a dispute has arisen requiring attention. The Court will hold a discovery conference on 4/30/2024, at 2:00 PM in Courtroom 6A. In preparation for this conference the parties shall follow the Discovery Matters and Disputes procedure as set forth in the Scheduling Order. Ordered by Judge Richard G. Andrews on 4/15/2024. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA, 1:23-cv-00401-RGA(nms) (Entered: 04/15/2024) (0) |
| Apr 12, 2024 | 177 | ORAL ORDER: The discovery conference scheduled for 4/23/2024, is now CANCELED. The parties have advised the dispute has been resolved. Ordered by Judge Richard G. Andrews on 4/12/2024. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA(nms) (Entered: 04/12/2024) (0) |
| Apr 8, 2024 | 176 | NOTICE OF SERVICE of (1) Novartis's Objections and Responses to Defendant Nanjing Noratech Pharmaceuticals Co., Limited's Second Set of Interrogatories to Plaintiff Novartis Pharmaceuticals Corporation (Nos. 4-8) and (2) Plaintiff's Supplemental Infringement Claim Chart for U.S. Patent No. 11,096,918 Against Nanjing Noratech Pharmaceuticals Co., Limited, and (3) Plaintiff's Supplemental Infringement Claim Chart for U.S. Patent No. 11,096,918 Against MSN Pharmaceuticals Inc., MSN Laboratories Private Limited, and MSN Life Sciences Private Limited filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 04/08/2024) (4) |
| Apr 5, 2024 | 174 | NOTICE OF SERVICE of Defendants' Joint Amended Invalidity Contentions for U.S. Patent No. 11,096,918 [HIGHLY CONFIDENTIAL] filed by Nanjing Noratech Pharmaceutical Co., Limited.(Gattuso, Dominick) (Entered: 04/05/2024) (2) |
| Apr 5, 2024 | 175 | NOTICE OF SERVICE of Nanjing Noratech Pharmaceutical Co., Limited's Amended Invalidity Contentions for U.S. Patent Nos.11,058,667 and 8,101,659 filed by Nanjing Noratech Pharmaceutical Co., Limited.(Gattuso, Dominick) (Entered: 04/05/2024) (2) |
| Apr 4, 2024 | 173 | NOTICE OF SERVICE of Defendant Nanjing Noratech Pharmaceutical Co., Limited's First Supplemental Responses and Objections to Plaintiff's First Set of Interrogatories (Nos. 1-3) filed by Nanjing Noratech Pharmaceutical Co., Limited.(Gattuso, Dominick) (Entered: 04/04/2024) (2) |
| Apr 3, 2024 | 171 | NOTICE OF SERVICE of (1) MSN Defendants Second Supplemental Responses and Objections to Plaintiffs Interrogatories Nos. 4 and 5 and (2) MSN Defendants Supplemental Responses and Objections to Plaintiffs First Set of Requests for Admission (Nos. 1-8) filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc..(Weinblatt, Richard) (Entered: 04/03/2024) (2) |
| Apr 3, 2024 | 172 | Official Transcript of Markman Hearing held on 3/12/24 before Judge Richard G. Andrews. Court Reporter Heather M. Triozzi,Email: Heather_Triozzi@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 4/24/2024. Redacted Transcript Deadline set for 5/6/2024. Release of Transcript Restriction set for 7/2/2024. (Triozzi, Heather) (Entered: 04/03/2024) (57) |
| Apr 2, 2024 | 168 | ORAL ORDER: The parties have advised that a dispute has arisen requiring attention. The Court will hold a discovery conference on 4/23/2024, at 2:00 PM in Courtroom 6A. In preparation for this conference the parties shall follow the Discovery Matters and Disputes procedure as set forth in the Scheduling Order. Ordered by Judge Richard G. Andrews on 4/2/2024. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA. (lah) (Entered: 04/02/2024) (0) |
| Apr 2, 2024 | 169 | NOTICE OF SERVICE of (1) MSN Pharmaceuticals Inc., MSN Laboratories Private Limited and MSN Life Sciences Private Limiteds Responses and Objections to Novartiss Notice of Deposition Under Fed. R. Civ. P. 30(b)(6), (2) Defendants Responses and Objections to Novartiss Second Set of Interrogatories Nos. 6-7 and (3) MSN Defendants Responses and Objections to Novartiss Second Set of Requests for the Production of Documents and Things (No. 28) filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc..(Weinblatt, Richard) (Entered: 04/02/2024) (2) |
| Apr 2, 2024 | 170 | NOTICE OF SERVICE of (1) MSN Pharmaceuticals Inc., MSN Laboratories Private Limited and MSN Life Sciences Private Limiteds Responses and Objections to Novartiss Notice of Deposition Under Fed. R. Civ. P. 30(b)(6) and (2) MSN Defendants Response and Objections to Plaintiffs Request for Admission filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc..(Weinblatt, Richard) (Entered: 04/02/2024) (2) |
| Apr 1, 2024 | 167 | NOTICE OF SERVICE of (i) Nanjing Noratech Pharmaceutical Co., Limited's Responses and Objections to Novartis Requests for Admission to Establish the Authenticity of Documents and/or Establish Documents as Business Records; (ii) Nanjing Noratech Pharmaceutical Co., Limited's Responses and Objections to Novartis Second Set of Interrogatories (Nos. 9-10); (iii) Nanjing Noratech Pharmaceutical Co., Limited's Responses and Objections to Novartis First Set of Requests For Admissions (Nos. 1-36) [HIGHLY CONFIDENTIAL-PURSUANT TO PROTECTIVE ORDER]; (iv) Noratechs Response to Novartis' First Set of Requests to Nanjing Noratech Pharmaceutical Co., Limited for the Production of Documents and Things (Nos. 1-37); and, (v) Responses and Objections to Notice of Deposition Under Fed. R. Civ. P. 30(b)(6) to Nanjing Noratech Pharmaceutical Co., Limited filed by Nanjing Noratech Pharmaceutical Co., Limited.(Gattuso, Dominick) (Entered: 04/01/2024) (3) |
| Mar 27, 2024 | 165 | Post-Markman Reply Supplemental Brief, filed by Nanjing Noratech Pharmaceutical Co., Limited. and MSN Defendants. (Gattuso, Dominick) Modified on 3/27/2024 (nms). (Entered: 03/27/2024) (3) |
| Mar 26, 2024 | 164 | Letter to The Honorable Richard G. Andrews, from Alexandra M. Joyce, regarding Novartis's supplemental claim construction pursuant to Courts Order at the Markman Hearing. (Attachments: # 1 Exhibit 1)(Joyce, Alexandra) Modified on 3/27/2024 (nms). (Entered: 03/26/2024) (0) |
| Mar 22, 2024 | 162 | NOTICE OF SERVICE of Novartis's Objections and Responses to Nanjing Noratech Pharmaceutical Co., Limited's Third Set of Requests for the Production of Document and Things (Nos. 24-27) filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 03/22/2024) (3) |
| Mar 22, 2024 | 163 | Letter to The Honorable Richard G. Andrews, from Dominick T. Gattuso and Richard Weinblatt, regarding post Markman Hearing supplement. (Gattuso, Dominick) Modified on 3/25/2024 (nms). (Entered: 03/22/2024) (5) |
| Mar 15, 2024 | 161 | NOTICE OF SERVICE of (1) Defendants Notice of Deposition of Bin Hu, (2) Defendants Notice of Deposition of Lili Feng, (3) Defendants Notice of Deposition of Mahavir Prashad, (4) Defendants Notice of Deposition of Michael J. Girgis, (5) Defendants Notice of Deposition of Paul Allen Sutton, (6) Defendants Notice of Deposition of Piotr Karpinski, (7) Defendants Notice of Deposition of Sven Erik Godtfredsen, (8) Defendants Notice of Deposition of Thomas J. Blacklock, and (9) Defendants Notice of Deposition of Yugang Liu filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc..(Weinblatt, Richard) (Entered: 03/15/2024) (2) |
| Mar 11, 2024 | 160 | NOTICE of Appearance by Maliheh Zare on behalf of Novartis Pharmaceuticals Corporation (Zare, Maliheh) (Entered: 03/11/2024) (1) |
| Mar 8, 2024 | 159 | ORAL ORDER: The Markman Hearing set for 3/12/2024, will now begin at 9:30 AM in Courtroom 6A. Ordered by Judge Richard G. Andrews on 3/8/2024. (nms) (Entered: 03/08/2024) (0) |
| Mar 6, 2024 | 158 | NOTICE OF SERVICE of Nanjing Noratech Pharmaceutical Co., Limited's Second Set of Interrogatories to Plaintiff Novartis Pharmaceuticals Corporation (Nos. 4-8) filed by Nanjing Noratech Pharmaceutical Co., Limited.(Gattuso, Dominick) (Entered: 03/06/2024) (2) |
| Mar 5, 2024 | 157 | REDACTED VERSION of 150 Stipulation of Dismissal, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 3/6/2024 (nms). (Entered: 03/05/2024) (4) |
| Mar 1, 2024 | 156 | NOTICE OF SERVICE of (1) Novartis's Requests for Admission to MSN Pharmaceuticals Inc., MSN Laboratories Private Limited, and MSN Life Sciences Private Limited to Establish the Authenticity of Documents or Establish Documents as Business Records, and (2) Novartis's Notice of Deposition Under Fed. R. Civ. P. 30(b)(6) to MSN Pharmaceuticals Inc., MSN Laboratories Private Limited, and MSN Life Sciences Private Limited filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 03/01/2024) (3) |
| Feb 29, 2024 | 152 | NOTICE OF SERVICE of (1) Novartis's Second Set of Interrogatories to MSN Pharmaceuticals Inc., MSN Laboratories Private Limited, and MSN Life Sciences Private Limited (Nos. 6-7); (2) Novartis's Second Set of Requests to MSN Pharmaceuticals Inc., MSN Laboratories Private Limited, and MSN Life Sciences Private Limited for the Production of Documents and Things; and (3) Novartis's Notice of Deposition Under Fed. R. Civ. P. 30(b)(6) to MSN Pharmaceuticals Inc., MSN Laboratories Private Limited, and MSN Life Sciences Private Limited filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 02/29/2024) (3) |
| Feb 29, 2024 | 153 | NOTICE OF SERVICE of (1) Novartis's Requests for Admission to Nanjing Noratech Pharmaceutical Co., Limited to Establish the Authenticity of Documents and/or Establish Documents as Business Record and (2) Novartis's Notice of Deposition Under Fed. R. Civ. P. 30(b)(6) to Nanjing Noratech Pharmaceutical Co., Limited filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 02/29/2024) (3) |
| Feb 29, 2024 | 154 | Joint Motion for Exemption of Persons from the District of Delaware's May 15, 2023 Standing Order on Personal Devices - filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Proposed Order)(Joyce, Alexandra) Modified on 2/29/2024 (nms). (Entered: 02/29/2024) (0) |
| Feb 29, 2024 | 155 | ORDER Granting Joint Motion for Exemption of Persons from the District of Delaware's May 15, 2023 Standing Order on Personal Devices ( (D.I. 154 in 22-cv-1395-RGA; D.I. 1291 in 20-md-2930-RGA). Signed by Judge Richard G. Andrews on 2/29/2024. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA(nms) (Entered: 02/29/2024) (2) |
| Feb 27, 2024 | 149 | SO ORDERED Granting (D.I. 148 in 22-cv-1395-RGA; D.I. 1281 in 20-md-2930-RGA) MOTION for Claim Construction Hearing. Signed by Judge Richard G. Andrews on 2/27/2024. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA(nms) (Entered: 02/27/2024) (4) |
| Feb 27, 2024 | 150 | [SEALED] STIPULATION of Dismissal by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 02/27/2024) (0) |
| Feb 27, 2024 | 151 | [SEALED] ORDER Granting (D.I. 124 in 22-cv-451-RGA; D.I. 1283 in 20-md-2930-RGA; D.I. 150 in 22-cv-1395-RGA) Stipulation and Order of Dismissal between Plaintiff and Defendant Mylan Pharmaceuticals Inc.. Signed by Judge Richard G. Andrews on 2/27/2024.*This order has been emailed to local counsel. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-00451-RGA, 1:22-cv-01395-RGA(nms) (Entered: 02/27/2024) (0) |
| Feb 23, 2024 | 146 | JOINT Claim Construction Brief Regarding U.S. Patent No. 11,096,918, filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 2/23/2024 (nms). (Entered: 02/23/2024) (30) |
| Feb 23, 2024 | 147 | Joint Appendix to 146 Joint Claim Construction Brief, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit A, # 2 Exhibits 1-10) (Joyce, Alexandra) Modified on 2/23/2024 (nms). (Entered: 02/23/2024) (0) |
| Feb 23, 2024 | 148 | MOTION for Claim Construction Hearing - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 2/23/2024 (nms). (Entered: 02/23/2024) (4) |
| Feb 21, 2024 | 145 | REDACTED VERSION of 139 Proposed Consent Judgment, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 2/22/2024 (nms). (Entered: 02/21/2024) (6) |
| Feb 20, 2024 | 144 | NOTICE OF SERVICE of Nanjing Noratech Pharmaceutical Co., Limited's Third Set of Requests for Production of Documents and Things to Plaintiff Novartis Pharmaceuticals Corporation (Nos. 24-27) filed by Nanjing Noratech Pharmaceutical Co., Limited.(Gattuso, Dominick) (Entered: 02/20/2024) (2) |
| Feb 13, 2024 | 143 | STIPULATION and Proposed Order to Extend Time to file public version of the [Proposed] Consent Judgment and Order of Injunction to February 20, 2024 - filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 2/13/2024 (nms). (Entered: 02/13/2024) (3) |
| Feb 9, 2024 | 142 | NOTICE OF SERVICE of Defendants' Sur-Reply Claim Construction Brief filed by Nanjing Noratech Pharmaceutical Co., Limited.(Gattuso, Dominick) (Entered: 02/09/2024) (2) |
| Feb 7, 2024 | 140 | [SEALED] Consent Judgment and Order of Injunction between Plaintiff and Defendants Alembic Global Holding SA, Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc.. Signed by Judge Richard G. Andrews on 2/7/2024.*This order has been emailed to local counsel. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-02021-RGA, 1:20-cv-00074-RGA, 1:22-cv-01395-RGA(nms) (Entered: 02/07/2024) (0) |
| Feb 6, 2024 | 139 | [SEALED] Proposed Consent Judgment and Order of Injunction, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 2/6/2024 (nms). (Entered: 02/06/2024) (0) |
| Jan 30, 2024 | 138 | REDACTED VERSION of 136 Sealed Stipulation, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 1/31/2024 (nms). (Entered: 01/30/2024) (5) |
| Jan 23, 2024 | 136 | [SEALED] STIPULATION and [Proposed] Order Staying Mylan Actions by Novartis Pharmaceuticals Corporation. (Silver, Daniel) (Entered: 01/23/2024) (0) |
| Jan 23, 2024 | 137 | [SEALED] SO ORDERED Granting (D.I. 136 in 22-cv-1395-RGA; D.I. 1238 in 20-md-2930-RGA; D.I. 121 in 22-cv-451-RGA) Stipulation and Proposed Order Staying Mylan Actions. Signed by Judge Richard G. Andrews on 1/23/2024.*This order has been emailed to local counsel. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-00451-RGA, 1:22-cv-01395-RGA(nms) (Entered: 01/23/2024) (0) |
| Jan 15, 2024 | 135 | NOTICE OF SERVICE of Novartis's Reply Claim Construction Brief Regarding U.S. Patent No. 11,096,918 filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 01/15/2024) (4) |
| Dec 22, 2023 | 134 | NOTICE OF SERVICE of Novartis's Supplemental Objections and Responses to Defendant Nanjing Noratech Pharmaceutical Co., Limited's First Set of Interrogatories to Plaintiff Novartis Pharmaceuticals Corporation (Nos. 1-3) filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 12/22/2023) (3) |
| Dec 19, 2023 | 133 | NOTICE to Take Deposition of Dr. Edmund J. Elder, Jr. filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 12/19/2023) (2) |
| Dec 18, 2023 | 132 | NOTICE OF SERVICE of (i) Nanjing Noratech Pharmaceutical Co., Limited's Responses and Objections to Novartis's Second Set of Interrogatories (No. 4-7); and, (ii) Nanjing Noratech Pharmaceutical Co., Limited's Response and Objections to Novartis's Second Set of Requests for the Production of Documents and Things (No. 29) filed by Nanjing Noratech Pharmaceutical Co., Limited.(Gattuso, Dominick) (Entered: 12/18/2023) (2) |
| Dec 15, 2023 | 131 | NOTICE OF SERVICE of Defendants' Answering Claim Construction Brief (with Exhibits A-G) filed by Nanjing Noratech Pharmaceutical Co., Limited.(Gattuso, Dominick) (Entered: 12/15/2023) (2) |
| Dec 13, 2023 | 130 | NOTICE OF SERVICE of (1) MSN Defendants Supplemental Responses and Objections to Plaintiffs Interrogatories Nos. 3, 4, and 5 and (2) MSN Defendants Supplemental Responses and Objections to Plaintiffs First Set of Requests for Admission (Nos. 1-9) filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc..(Weinblatt, Richard) (Entered: 12/13/2023) (2) |
| Dec 1, 2023 | 129 | REDACTED VERSION of 125 Letter, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 12/4/2023 (nms). (Entered: 12/01/2023) (6) |
| Nov 29, 2023 | 128 | REDACTED VERSION of 120 Letter, by Nanjing Noratech Pharmaceutical Co., Limited. (Attachments: # 1 Exhibits A-J)(Gattuso, Dominick) Modified on 11/29/2023 (nms). (Entered: 11/29/2023) (0) |
| Nov 27, 2023 | 126 | STIPULATION and Order to Extend Time to file redacted version of discovery dispute letter to 12/1/2023 - filed by Nanjing Noratech Pharmaceutical Co., Limited. (Gattuso, Dominick) Modified on 11/27/2023 (nms). (Entered: 11/27/2023) (3) |
| Nov 27, 2023 | 127 | SO ORDERED Granting (D.I. 1204 in 20-md-2930-RGA; D.I. 124 in 22-cv-1395-RGA) Stipulation and Proposed Order Dismissing Mylan Laboratories Limited and Viatris, Inc. and Amending Caption. Signed by Judge Richard G. Andrews on 11/27/2023. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA(nms) (Entered: 11/27/2023) (4) |
| Nov 21, 2023 | 124 | STIPULATION and [Proposed] Order Dismissing Mylan Laboratories Limited and Viatris Inc. and Amending Caption by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 11/21/2023) (4) |
| Nov 21, 2023 | 125 | [SEALED] Letter to The Honorable Richard G. Andrews, from Daniel M. Silver, Esq., regarding response to Noratech's letter concerning discovery dispute. (Attachments: # 1 Certificate of Service)(Silver, Daniel) Modified on 11/21/2023 (nms). (Entered: 11/21/2023) (0) |
| Nov 20, 2023 | 122 | NOTICE OF SERVICE of Novartis's Opening Claim Construction Brief Regarding U.S. Patent No. 11,096,918 filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 11/20/2023) (4) |
| Nov 20, 2023 | 123 | NOTICE OF SERVICE of (1) Novartis's Second Set of Interrogatories to Nanjing Noratech Pharmaceutical Co., Limited (Nos. 47) and (2) Novartis's Second Set of Requests to Nanjing Noratech Pharmaceutical Co., Limited For the Production of Documents and Things (No. 29) filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 11/20/2023) (3) |
| Nov 17, 2023 | 120 | [SEALED] Letter to The Honorable Richard G. Andrews, from Dominick T. Gattuso, Esq., regarding discovery dispute. (Attachments: # 1 Exhibits A-J, # 2 Certificate of Service)(Gattuso, Dominick) Modified on 11/20/2023 (nms). (Entered: 11/17/2023) (0) |
| Nov 17, 2023 | 121 | PROPOSED Order for 120 Letter, by Nanjing Noratech Pharmaceutical Co., Limited. (Gattuso, Dominick) Modified on 11/20/2023 (nms). (Entered: 11/17/2023) (2) |
| Nov 14, 2023 | 119 | ORAL ORDER: The parties have advised that a dispute has arisen requiring attention. The Court will hold a discovery conference on 11/30/2023 at 2:00 PM in Courtroom 6A. In preparation for this conference the parties shall follow the Discovery Matters and Disputes procedure as set forth in the Scheduling Order. Ordered by Judge Richard G. Andrews on 11/14/2023. Associated Cases: 1:20-md-02930-RGA, 1:23-cv-401-RGA, 1:22-cv-01395-RGA (lah) Modified on 11/20/2023 (lah). (Entered: 11/14/2023) (0) |
| Nov 8, 2023 | 118 | NOTICE OF SERVICE of Novartis's Objections and Responses to Nanjing Noratech Pharmaceutical Co., Limited's Second Set of Requests for the Production of Documents and Things (Nos. 18-23) filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 11/08/2023) (2) |
| Oct 20, 2023 | 117 | Joint Claim Construction Chart, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibits 1-10, # 2 Exhibits 11-25)(Joyce, Alexandra) Modified on 10/20/2023 (nms). (Entered: 10/20/2023) (0) |
| Oct 13, 2023 | 116 | ANSWER to 1 Complaint,, by Nanjing Noratech Pharmaceutical Co., Limited.(Gattuso, Dominick) (Entered: 10/13/2023) (21) |
| Oct 11, 2023 | 115 | NOTICE of Appearance by Denise Seastone Kraft on behalf of Nanjing Noratech Pharmaceutical Co., Limited (Kraft, Denise) (Entered: 10/11/2023) (1) |
| Oct 9, 2023 | 113 | NOTICE OF SERVICE of Defendant Nanjing Noratech Pharmaceutical Co., Limited's Second Set of Requests for Production of Documents and Things to Plaintiff Novartis Pharmaceuticals Corporation (Nos. 18-23) filed by Nanjing Noratech Pharmaceutical Co., Limited.(Gattuso, Dominick) (Entered: 10/09/2023) (2) |
| Oct 9, 2023 | 114 | NOTICE OF SERVICE of Novartis's Rebuttal Proposed Construction of Claim Term and Evidence for U.S. Patent No. 11,096,918 filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) (Entered: 10/09/2023) (4) |
| Sep 29, 2023 | 111 | MEMORANDUM OPINION. Signed by Judge Richard G. Andrews on 9/29/2023. (lah) (Main Document 111 replaced on 10/16/2023) (nms). (Entered: 09/29/2023) (10) |
| Sep 29, 2023 | 112 | ORDER: Noratech's motion to dismiss (D.I. 26 ) and MSN's motion for judgment on the pleadings (D.I. 65 ) are DENIED. Signed by Judge Richard G. Andrews on 9/29/2023. (lah) (Main Document 112 replaced on 10/16/2023) (nms). (Entered: 09/29/2023) (1) |
| Sep 26, 2023 | 109 | NOTICE OF SERVICE of (1) MSN Defendants Responses and Objections to Plaintiffs First Set of Requests for Admission (Nos. 1-9), (2) MSN Defendants Responses and Objections to Plaintiffs First Set of Requests for the Production of Documents and Things (Nos. 1-27), and (3) MSN Defendants Responses and Objections to Plaintiffs First Set of Interrogatories (Nos. 1-5) filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc..(Weinblatt, Richard) (Entered: 09/26/2023) (2) |
| Sep 26, 2023 | 110 | NOTICE OF SERVICE of Responses And Objections To Novartis's First Set Of Requests To Mylan Pharmaceuticals Inc., Mylan Laboratories Limited, And Viatris Inc. For The Production Of Documents And Things [Highly Confidential-Attorneys' Eyes Only]; and Responses And Objections To Novartis's First Set Of Interrogatories To Mylan Pharmaceuticals Inc., Mylan Laboratories Limited, And Viatris Inc. (Nos. 1-3) [Highly Confidential-Attorneys' Eyes Only] filed by Mylan Pharmaceuticals Inc., Mylan Laboratories Limited, Viatris Inc..(Palapura, Bindu) (Entered: 09/26/2023) (2) |
| Sep 25, 2023 | 107 | NOTICE OF SERVICE of Defendants Alembic Pharmaceuticals Limited and Alembic Pharmaceuticals, Inc.'s Responses and Objections to Plaintiff Novartis Pharmaceuticals Corporation's, (1) First Set of Interrogatories (Nos. 1-4); (2) First Set of Requests for Admission (Nos. 1-5); and (3) First Set of Requests or the Production of Documents and Things (Nos. 1-27) filed by Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc..(Taylor, Daniel) (Entered: 09/25/2023) (2) |
| Sep 25, 2023 | 108 | NOTICE OF SERVICE of (i) Defendant Nanjing Noratech Pharmaceutical Co., Limited's Responses and Objections to Plaintiff's First Set of Requests for Production [HIGHLY CONFIDENTIAL] and; (ii) Defendant Nanjing Noratech Pharmaceutical Co., Limited's Responses and Objections to Plaintiffs First Set of Interrogatories (Nos. 1-3) filed by Nanjing Noratech Pharmaceutical Co., Limited.(Gattuso, Dominick) (Entered: 09/25/2023) (2) |
| Sep 14, 2023 | 106 | MOTION for Pro Hac Vice Appearance of Attorney Thomas P. Heneghan of the law firm of Husch Blackwell LLP - filed by Nanjing Noratech Pharmaceutical Co., Limited. (Gattuso, Dominick) (Entered: 09/14/2023) (4) |
| Sep 11, 2023 | 105 | NOTICE OF SERVICE of Defendants' Preliminary Claim Constructions and Supporting Evidence [HIGHLY CONFIDENTIAL] filed by Mylan Pharmaceuticals Inc., Alembic Global Holding SA, Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc., Crystal Pharmaceutical (Suzhou) Co., Ltd., MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc., Mylan Laboratories Limited, Nanjing Noratech Pharmaceutical Co., Limited, Viatris Inc..(Palapura, Bindu) (Entered: 09/11/2023) (2) |
| Sep 8, 2023 | 104 | NOTICE OF SERVICE of (1) Novartis's Objections and Responses to Defendant Nanjing Noratech Pharmaceutical Co., Limited's First Set of Interrogatories to Plaintiff Novartis Pharmaceuticals Corporation (Nos. 1-3) (C.A. No. 22-1395-RGA), and (2) Novartis's Responses and Objections to Defendant Nanjing Noratech Pharmaceutical Co., Limited's First Set of Interrogatories (Nos. 1-2) (C.A. No. 23-401-RGA) filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 09/08/2023) (3) |
| Aug 29, 2023 | 103 | NOTICE OF SERVICE of (1) Novartis's Objections and Responses to Defendants' First Set of Joint Requests for the Production of Documents and Things (Nos. 1-39), (2) Novartis's Objections and Responses to Noratech's First Set of Requests for the Production of Documents and Things (Nos. 1-17), and (3) Novartis's Objections and Responses to Alembic's First Set of Requests for the Production of Documents and Things (Nos. 1-7) filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 08/29/2023) (5) |
| Aug 23, 2023 | 102 | NOTICE OF SERVICE of (1) Novartis's First Set of Interrogatories to Defendants, (2) Novartis's First Set of Requests to Defendants for the Production of Documents and Things, and (3) Novartis's First Set of Requests for Admission to Defendants filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 08/23/2023) (5) |
| Aug 17, 2023 | 101 | NOTICE OF SERVICE of (1) Objections and Responses to MSN's First Interrogatory, and (2) Objections and Responses to MSN's First Set of Joint Requests for the Production of Documents and Things (Nos. 1-4) filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 08/17/2023) (2) |
| Aug 8, 2023 | 100 | NOTICE OF SERVICE of Defendant Nanjing Noratech Pharmaceutical Co., Limited's First Set of Interrogatories to Plaintiff Novartis Pharmaceuticals Corporation (Nos. 1-3) filed by Nanjing Noratech Pharmaceutical Co., Limited.(Gattuso, Dominick) (Entered: 08/08/2023) (2) |
| Aug 4, 2023 | 98 | NOTICE OF SERVICE of Defendant Nanjing Noratech Pharmaceutical Co., Limited's Initial Invalidity Contentions for U.S. Patent Nos.11,058,667 and 8,101,659 filed by Nanjing Noratech Pharmaceutical Co., Limited.(Gattuso, Dominick) (Entered: 08/04/2023) (2) |
| Aug 4, 2023 | 99 | NOTICE OF SERVICE of Defendants Joint Initial Invalidity Contentions filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc..(Weinblatt, Richard) (Entered: 08/04/2023) (2) |
| Jul 28, 2023 | 97 | NOTICE OF SERVICE of Defendants' First Set of Joint Requests for the Production of Documents and Things (Nos. 1-39) to Plaintiff Novartis Pharmaceuticals Corporation filed by Mylan Pharmaceuticals Inc., Mylan Laboratories Limited.(Palapura, Bindu) (Entered: 07/28/2023) (2) |
| Jul 27, 2023 | 95 | NOTICE OF SERVICE of Defendants Alembic Pharmaceuticals Limited and Alembic Pharmaceuticals, Inc.'s First Set of Requests for the Production of Documents and Things (Nos. 1-7) filed by Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc..(Taylor, Daniel) (Entered: 07/27/2023) (2) |
| Jul 27, 2023 | 96 | NOTICE OF SERVICE of Defendant Nanjing Noratech Pharmaceutical Co., Limiteds First Set of Requests for Production of Documents and Things to Plaintiff Novartis Pharmaceuticals Corporation (Nos. 1-17) filed by Nanjing Noratech Pharmaceutical Co., Limited.(Gattuso, Dominick) (Entered: 07/27/2023) (2) |
| Jul 24, 2023 | 94 | NOTICE OF SERVICE of Defendants Alembic Pharmaceuticals Limited and Alembic Pharmaceuticals, Inc.'s updated ANDA documents and FDA correspondence filed by Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc..(Taylor, Daniel) (Entered: 07/24/2023) (2) |
| Jul 17, 2023 | 92 | NOTICE OF SERVICE of Defendants Mylan Pharmaceuticals Inc.'s, Mylan Laboratories Limited's And Viatris Inc.'s Initial Disclosures Pursuant To Rule 26(A)(1) And Paragraph 3 Of The Delaware Default Standard For Discovery filed by Mylan Pharmaceuticals Inc., Mylan Laboratories Limited.(Palapura, Bindu) (Entered: 07/17/2023) (2) |
| Jul 17, 2023 | 93 | NOTICE OF SERVICE of (1) Defendants MSN Pharmaceuticals Inc., MSN Laboratories Private Limited, and MSN Life Sciences Private Limiteds First Set of Requests for Documents and Things (Nos. 1-4) to Plaintiff Novartis Pharmaceuticals Corporation and (2) Defendants MSN Pharmaceuticals Inc., MSN Laboratories Private Limited, and MSN Life Sciences Private Limiteds First Interrogatory to Novartis Pharmaceuticals Corporation filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc..(Weinblatt, Richard) (Entered: 07/17/2023) (2) |
| Jul 14, 2023 | 90 | NOTICE OF SERVICE of (1) Novartis's Rule 26(a) Initial Disclosures regarding the '659 and '667 Patents, (2) Novartis's Initial Paragraph 3 Disclosures Regarding Electronic Systems Information regarding the '659 and '667 Patents, and (3) Novartis's Initial Infringement Charts Against Defendants regarding the '659 and '667 Patents filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 07/14/2023) (5) |
| Jul 14, 2023 | 91 | MOTION for Pro Hac Vice Appearance of Attorney Matthew M. Kamps of Husch Blackwell LLP - filed by Nanjing Noratech Pharmaceutical Co., Limited. (Gattuso, Dominick) (Entered: 07/14/2023) (4) |
| Jul 13, 2023 | 87 | NOTICE OF SERVICE of Defendants Alembic Pharmaceuticals Limited and Alembic Pharmaceuticals, Inc.'s Initial Disclosures, Including Discovery of Electronically Stored Information ("ESI") (the "Default Standard") filed by Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc..(Taylor, Daniel) (Entered: 07/13/2023) (2) |
| Jul 13, 2023 | 88 | NOTICE OF SERVICE of (1) MSN Laboratories Private Limiteds and MSN Pharmaceuticals Inc.s Initial Rule 26(a)(1) Disclosures and (2) MSN Laboratories Private Limiteds and MSN Pharmaceuticals Inc.s Initial ESI Disclosures filed by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc..(Weinblatt, Richard) (Entered: 07/13/2023) (2) |
| Jul 13, 2023 | 89 | NOTICE OF SERVICE of Defendant Nanjing Noratech Pharmaceutical Co., Limited's Fed. R. Civ. P. Rule 26(a)(1)(A) and Paragraph 3 Disclosures filed by Nanjing Noratech Pharmaceutical Co., Limited.(Gattuso, Dominick) (Entered: 07/13/2023) (2) |
| Jul 7, 2023 | 86 | REDACTED VERSION of 82 Stipulation and Proposed Order, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 7/7/2023 (nms). (Entered: 07/07/2023) (6) |
| Jul 6, 2023 | 85 | SCHEDULING ORDER: Joinder of Parties due by 11/3/2023. Amended Pleadings due by 11/3/2023. Fact Discovery completed by 4/5/2024. Joint Claim Construction Brief due by 2/23/2024. A Markman Hearing is set for 3/12/2024, at 9:00 AM in Courtroom 6A. A Pretrial Conference is set for 11/22/2024, at 9:00 AM in Courtroom 6A. A Bench Trial is set to start 12/9/2024, at 8:30 AM in Courtroom 6A (see Order for further details). Signed by Judge Richard G. Andrews on 7/6/2023. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA(nms) (Entered: 07/06/2023) (18) |
| Jul 5, 2023 | 84 | PROPOSED Scheduling Order, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 7/6/2023 (nms). (Entered: 07/05/2023) (18) |
| Jun 30, 2023 | 82 | [SEALED] STIPULATION and [Proposed] Order, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 6/30/2023 (nms). (Entered: 06/30/2023) (0) |
| Jun 30, 2023 | 83 | [SEALED] ORDER Granting (16 in 23-cv-401-RGA; 82 in 22-cv-1395-RGA; 176 in 21-cv-1330-RGA; 1091 in 20-md-2930-RGA; 95 in 22-cv-451-RGA) Stipulation and Proposed Order. Signed by Judge Richard G. Andrews on 6/30/2023.*This order has been emailed to local counsel. Associated Cases: 1:20-md-02930-RGA, 1:21-cv-01330-RGA, 1:22-cv-00451-RGA, 1:22-cv-01395-RGA, 1:23-cv-00401-RGA(nms) (Entered: 06/30/2023) (0) |
| Jun 29, 2023 | 81 | MOTION for Pro Hac Vice Appearance of Attorney Melinda R. Roberts - filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certification for Melinda R. Roberts)(Silver, Daniel) (Entered: 06/29/2023) (Main Document) (4) |
| Jun 29, 2023 | 81 | MOTION for Pro Hac Vice Appearance of Attorney Melinda R. Roberts - filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certification for Melinda R. Roberts)(Silver, Daniel) (Entered: 06/29/2023) (Certification for Melinda R. Roberts) (1) |
| Jun 21, 2023 | 80 | REDACTED VERSION of 79 Reply Brief, by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc.. (Attachments: # 1 Exhibits D-F)(Weinblatt, Richard) Modified on 6/22/2023 (nms). (Entered: 06/21/2023) (Main Document) (11) |
| Jun 21, 2023 | 80 | REDACTED VERSION of 79 Reply Brief, by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc.. (Attachments: # 1 Exhibits D-F)(Weinblatt, Richard) Modified on 6/22/2023 (nms). (Entered: 06/21/2023) (Exhibit D-F) (30) |
| Jun 6, 2023 | 77 | REDACTED VERSION of 70 Answering Brief in Opposition, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 6/6/2023 (nms). (Entered: 06/06/2023) (18) |
| Jun 6, 2023 | 78 | REDACTED VERSION of 71 Declaration, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 6/6/2023 (nms). (Entered: 06/06/2023) (25) |
| Jun 6, 2023 | 79 | [SEALED] REPLY BRIEF re 65 MOTION for Judgment on the Pleadings filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc.. (Attachments: # 1 Exhibits D-F)(Weinblatt, Richard) (Entered: 06/06/2023) (0) |
| Jun 5, 2023 | 76 | REDACTED VERSION of 66 Opening Brief in Support, by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc.. (Attachments: # 1 Exhibit A-C)(Stamoulis, Stamatios) (Entered: 06/05/2023) (Main Document) (16) |
| Jun 5, 2023 | 76 | REDACTED VERSION of 66 Opening Brief in Support, by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc.. (Attachments: # 1 Exhibit A-C)(Stamoulis, Stamatios) (Entered: 06/05/2023) (Exhibit A-C) (30) |
| Jun 2, 2023 | 74 | REDACTED VERSION of 67 Proposed Consent Judgment, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 6/2/2023 (nms). (Entered: 06/02/2023) (6) |
| Jun 2, 2023 | 75 | REDACTED VERSION of 68 Consent Judgment, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 06/02/2023) (6) |
| Jun 1, 2023 | 72 | ORAL ORDER: Due to a scheduling conflict the Rule 16(b) Conference set for 6/1/2023, will now commence at 4:00 PM in Courtroom 6A. Signed by Judge Richard G. Andrews on 6/1/2023. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA, 1:23-cv-00401-RGA(nms) (Entered: 06/01/2023) (0) |
| Jun 1, 2023 | 73 | Amended Proposed Scheduling Order, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 6/1/2023 (nms). (Entered: 06/01/2023) (19) |
| May 30, 2023 | 68 | [SEALED] CONSENT JUDGMENT and Order of Injunction between Crystal Pharmaceutical (Suzhou) Co., Ltd. and Novartis Pharmaceuticals Corporation. Signed by Judge Richard G. Andrews on 5/30/2023.This order has been emailed to local counsel. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-01979-RGA, 1:21-cv-01452-RGA, 1:22-cv-01395-RGA(nms) (Entered: 05/30/2023) (0) |
| May 30, 2023 | 69 | PROPOSED Scheduling Order, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 5/30/2023 (nms). (Entered: 05/30/2023) (20) |
| May 30, 2023 | 70 | [SEALED] ANSWERING BRIEF in Opposition re 65 MOTION for Judgment on the Pleadings filed by Novartis Pharmaceuticals Corporation.Reply Brief due date per Local Rules is 6/6/2023. (Attachments: # 1 Certificate of Service)(Silver, Daniel) (Entered: 05/30/2023) (0) |
| May 30, 2023 | 71 | [SEALED] DECLARATION of Christopher Loh re 70 Answering Brief in Opposition, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibits A-F, # 2 Certificate of Service)(Silver, Daniel) Modified on 5/31/2023 (nms). (Entered: 05/30/2023) (0) |
| May 26, 2023 | 67 | [SEALED] Proposed Consent Judgment and Order of Injunction between Plaintiff and Crystal Defendant, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 5/26/2023 (nms). (Entered: 05/26/2023) (0) |
| May 22, 2023 | 65 | MOTION for Judgment on the Pleadings - filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc.. (Weinblatt, Richard) (Entered: 05/22/2023) (2) |
| May 22, 2023 | 66 | [SEALED] OPENING BRIEF in Support re 65 MOTION for Judgment on the Pleadings filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc..Answering Brief/Response due date per Local Rules is 6/5/2023. (Attachments: # 1 Exhibits A-C)(Weinblatt, Richard) (Entered: 05/22/2023) (0) |
| May 18, 2023 | 64 | MOTION for Pro Hac Vice Appearance of Attorney Melanie Black Dubis of Parker Poe Adams & Bernstein LLP - filed by Mylan Pharmaceuticals Inc., Mylan Laboratories Limited, Viatris Inc.. (Moore, David) (Entered: 05/18/2023) (3) |
| Apr 13, 2023 | 62 | Order Setting Rule 16(b) Conference: A Scheduling Conference is set for 6/1/2023, at 3:30 PM in Courtroom 6A (see Order for further details). Signed by Judge Richard G. Andrews on 4/13/2023. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA(nms) (Entered: 04/13/2023) (1) |
| Apr 13, 2023 | 63 | NOTICE of Appearance by Daniel Taylor on behalf of Alembic Global Holding SA, Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc. (Taylor, Daniel) (Entered: 04/13/2023) (1) |
| Apr 11, 2023 | 61 | SO ORDERED Granting (D.I. 983 in 20-md-2930-RGA; D.I. 60 in 22-cv-1395-RGA) Stipulation and Proposed Order to Bifurcate and Stay Certain Defenses and Counterclaims. Signed by Judge Richard G. Andrews on 4/11/2023. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA(nms) (Entered: 04/11/2023) (5) |
| Apr 10, 2023 | 60 | STIPULATION and [Proposed] Order to Bifurcate and Stay Certain Defenses and Counterclaims by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 04/10/2023) (5) |
| Mar 22, 2023 | 59 | NOTICE of Change of Address by Alexandra M. Joyce (Joyce, Alexandra) (Entered: 03/22/2023) (5) |
| Mar 20, 2023 | 57 | ANSWER to 1 Complaint with Additional Defenses, by Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc., amd Alembic Global Holding SA.(Belgam, Neal) Modified on 3/20/2023 (nms). Modified on 3/21/2023 (nms). (Entered: 03/20/2023) (30) |
| Mar 20, 2023 | 58 | Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed, filed by Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc., and Alembic Global Holding SA. (Belgam, Neal) Modified on 3/21/2023 (nms). (Entered: 03/20/2023) (2) |
| Mar 17, 2023 | 56 | NOTICE of Withdrawal of Appearance of Delaware Counsel, Eve Ormerod by Alembic Global Holding SA, Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc. (Ormerod, Eve) (Entered: 03/17/2023) (1) |
| Mar 15, 2023 | 55 | ANSWER to 47 Answer to Complaint, Counterclaim by Novartis Pharmaceuticals Corporation.(Silver, Daniel) (Entered: 03/15/2023) (30) |
| Feb 7, 2023 | 54 | ANSWER to 49 Answer to Complaint, and Counterclaims, by Novartis Pharmaceuticals Corporation.(Silver, Daniel) Modified on 2/8/2023 (nms). (Entered: 02/07/2023) (7) |
| Feb 6, 2023 | 53 | STIPULATION and Order to Extend Time - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 2/6/2023 (nms). (Entered: 02/06/2023) (3) |
| Jan 18, 2023 | 50 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Mylan Inc. for Mylan Laboratories Limited, Mylan Pharmaceuticals Inc.; Corporate Parent none for Viatris Inc. filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc.. (Palapura, Bindu) (Entered: 01/18/2023) (2) |
| Jan 18, 2023 | 51 | Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Nanjing Noratech Pharmaceutical Co., Limited. (Gattuso, Dominick) (Entered: 01/18/2023) (2) |
| Jan 18, 2023 | 52 | MOTION for Pro Hac Vice Appearance of Attorney Robert L. Florence and Tasneem A. Dharamsi of Parker Poe Adams & Bernstein LLP - filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc.. (Moore, David) (Entered: 01/18/2023) (4) |
| Jan 17, 2023 | 47 | ANSWER to 1 Complaint, with Jury Demand and COUNTERCLAIMS against All Plaintiffs, by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) Modified on 1/18/2023 (nms). (Entered: 01/17/2023) (30) |
| Jan 17, 2023 | 48 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Crystal Pharmatech Co., Ltd. for Crystal Pharmaceutical (Suzhou) Co., Ltd. filed by Crystal Pharmaceutical (Suzhou) Co., Ltd.. (Gattuso, Dominick) (Entered: 01/17/2023) (2) |
| Jan 17, 2023 | 49 | ANSWER to 1 Complaint, Affirmative Defenses and COUNTERCLAIMS against Novartis Pharmaceuticals Corporation, by Mylan Pharmaceuticals Inc., Viatris Inc., Mylan Laboratories Limited.(Palapura, Bindu) Modified on 1/18/2023 (nms). (Entered: 01/17/2023) (30) |
| Jan 13, 2023 | 46 | STIPULATION and Order to Extend Time for Crystal to answer, move or otherwise respond to the Complaint to January 17, 2023 - filed by Crystal Pharmaceutical (Suzhou) Co., Ltd.. (Gattuso, Dominick) Modified on 1/13/2023 (nms). (Entered: 01/13/2023) (3) |
| Jan 6, 2023 | 42 | STIPULATION and Proposed Order to Extend Time to answer, move, or otherwise respond to the Complaint to March 20, 2023 - filed by Alembic Global Holding SA, Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc.. (Ormerod, Eve) Modified on 1/6/2023 (nms). (Entered: 01/06/2023) (2) |
| Jan 6, 2023 | 43 | ANSWER to 33 Answer to Complaint, Counterclaim by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 01/06/2023) (13) |
| Jan 6, 2023 | 44 | REPLY BRIEF re 26 MOTION to Dismiss for Failure to State a Claim filed by Nanjing Noratech Pharmaceutical Co., Limited. (Gattuso, Dominick) (Entered: 01/06/2023) (14) |
| Jan 6, 2023 | 45 | REQUEST for Oral Argument by Nanjing Noratech Pharmaceutical Co., Limited re 26 MOTION to Dismiss for Failure to State a Claim . (Gattuso, Dominick) (Entered: 01/06/2023) (2) |
| Dec 29, 2022 | 40 | REDACTED VERSION of 37 Answering Brief in Opposition, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 12/29/2022 (nms). (Entered: 12/29/2022) (20) |
| Dec 29, 2022 | 41 | REDACTED VERSION of 38 Declaration of Christopher E. Loh, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 12/29/2022 (nms). (Entered: 12/29/2022) (9) |
| Dec 27, 2022 | 39 | STIPULATION and Order to Extend Time - filed by Nanjing Noratech Pharmaceutical Co., Limited. (Gattuso, Dominick) Modified on 12/27/2022 (nms). (Entered: 12/27/2022) (3) |
| Dec 22, 2022 | 37 | [SEALED] ANSWERING BRIEF in Opposition re 26 MOTION to Dismiss for Failure to State a Claim filed by Novartis Pharmaceuticals Corporation.Reply Brief due date per Local Rules is 12/29/2022. (Attachments: # 1 Certificate of Service)(Silver, Daniel) (Entered: 12/22/2022) (0) |
| Dec 22, 2022 | 38 | [SEALED] DECLARATION of Christopher E. Loh re 37 Answering Brief in Opposition, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certificate of Service)(Silver, Daniel) Modified on 12/22/2022 (nms). (Entered: 12/22/2022) (0) |
| Dec 19, 2022 | 36 | MOTION for Pro Hac Vice Appearance of Attorney Ronald M. Daignault and Richard Juang - filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc.. (Weinblatt, Richard) (Entered: 12/19/2022) (6) |
| Dec 16, 2022 | 33 | ANSWER to 1 Complaint, and COUNTERCLAIMS against Novartis Pharmaceuticals Corporation, by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., MSN Life Sciences Private Limited.(Weinblatt, Richard) Modified on 12/19/2022 (nms). (Entered: 12/16/2022) (30) |
| Dec 16, 2022 | 34 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent MSN Laboratories Pvt. Ltd. for MSN Life Sciences Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc., MSN Pharmaceuticals Inc. filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc.. (Weinblatt, Richard) (Entered: 12/16/2022) (2) |
| Dec 16, 2022 | 35 | STIPULATION and Order to Extend Time to Respond to Complaint - filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc.. (Palapura, Bindu) Modified on 12/19/2022 (nms). Modified on 12/19/2022 (nms). (Entered: 12/16/2022) (2) |
| Dec 14, 2022 | 32 | STIPULATION and Order to Extend Time - filed by Crystal Pharmaceutical (Suzhou) Co., Ltd.. (Gattuso, Dominick) Modified on 12/14/2022 (nms). (Entered: 12/14/2022) (3) |
| Dec 6, 2022 | 31 | REDACTED VERSION of 27 Opening Brief in Support, by Nanjing Noratech Pharmaceutical Co., Limited. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Certificate of Service)(Gattuso, Dominick) (Entered: 12/06/2022) (Main Document) (16) |
| Dec 6, 2022 | 31 | REDACTED VERSION of 27 Opening Brief in Support, by Nanjing Noratech Pharmaceutical Co., Limited. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Certificate of Service)(Gattuso, Dominick) (Entered: 12/06/2022) (Exhibit A) (6) |
| Dec 6, 2022 | 31 | REDACTED VERSION of 27 Opening Brief in Support, by Nanjing Noratech Pharmaceutical Co., Limited. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Certificate of Service)(Gattuso, Dominick) (Entered: 12/06/2022) (Exhibit B) (4) |
| Dec 6, 2022 | 31 | REDACTED VERSION of 27 Opening Brief in Support, by Nanjing Noratech Pharmaceutical Co., Limited. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Certificate of Service)(Gattuso, Dominick) (Entered: 12/06/2022) (Exhibit C) (27) |
| Dec 6, 2022 | 31 | REDACTED VERSION of 27 Opening Brief in Support, by Nanjing Noratech Pharmaceutical Co., Limited. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Certificate of Service)(Gattuso, Dominick) (Entered: 12/06/2022) (Exhibit D) (10) |
| Dec 6, 2022 | 31 | REDACTED VERSION of 27 Opening Brief in Support, by Nanjing Noratech Pharmaceutical Co., Limited. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Certificate of Service)(Gattuso, Dominick) (Entered: 12/06/2022) (Certificate of Service) (1) |
| Nov 28, 2022 | 30 | STIPULATION and Proposed Order to Extend Time - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 11/28/2022 (nms). (Entered: 11/28/2022) (2) |
| Nov 23, 2022 | 28 | ORDER Granting Motion for Leave to File Under Seal (D.I. 25 ). Signed by Judge Richard G. Andrews on 11/23/2022. (nms) (Entered: 11/23/2022) (2) |
| Nov 23, 2022 | 29 | STIPULATION and Proposed Order to Extend Time - filed by Alembic Global Holding SA, Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc.. (Ormerod, Eve) Modified on 11/23/2022 (nms). (Entered: 11/23/2022) (2) |
| Nov 22, 2022 | 25 | MOTION for Leave to File Under Seal - filed by Nanjing Noratech Pharmaceutical Co., Limited. (Attachments: # 1 Proposed Order, # 2 Exhibit 1)(Gattuso, Dominick) Modified on 11/22/2022 (nms). (Entered: 11/22/2022) (Main Document) (4) |
| Nov 22, 2022 | 26 | MOTION to Dismiss for Failure to State a Claim - filed by Nanjing Noratech Pharmaceutical Co., Limited. (Attachments: # 1 Text of Proposed Order)(Gattuso, Dominick) (Entered: 11/22/2022) (Main Document) (2) |
| Nov 22, 2022 | 27 | [SEALED] OPENING BRIEF in Support re 26 MOTION to Dismiss for Failure to State a Claim filed by Nanjing Noratech Pharmaceutical Co., Limited.Answering Brief/Response due date per Local Rules is 12/6/2022. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Certificate of Service)(Gattuso, Dominick) (Entered: 11/22/2022) (0) |
| Nov 22, 2022 | 25 | MOTION for Leave to File Under Seal - filed by Nanjing Noratech Pharmaceutical Co., Limited. (Attachments: # 1 Proposed Order, # 2 Exhibit 1)(Gattuso, Dominick) Modified on 11/22/2022 (nms). (Entered: 11/22/2022) (Text of Proposed Order) (2) |
| Nov 22, 2022 | 25 | MOTION for Leave to File Under Seal - filed by Nanjing Noratech Pharmaceutical Co., Limited. (Attachments: # 1 Proposed Order, # 2 Exhibit 1)(Gattuso, Dominick) Modified on 11/22/2022 (nms). (Entered: 11/22/2022) (Exhibit 1) (3) |
| Nov 22, 2022 | 26 | MOTION to Dismiss for Failure to State a Claim - filed by Nanjing Noratech Pharmaceutical Co., Limited. (Attachments: # 1 Text of Proposed Order)(Gattuso, Dominick) (Entered: 11/22/2022) (Text of Proposed Order) (2) |
| Nov 21, 2022 | 23 | DECLARATION of Service of MSN Laboratories Private Limited, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 11/21/2022 (nms). (Entered: 11/21/2022) (2) |
| Nov 21, 2022 | 24 | DECLARATION of Service of MSN Life Sciences Private Limited, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 11/21/2022 (nms). (Entered: 11/21/2022) (2) |
| Nov 18, 2022 | 21 | MOTION for Pro Hac Vice Appearance of Attorney Don J. Mizerk and Matthew M. Kamps, each of the law firm of Husch Blackwell LLP - filed by Nanjing Noratech Pharmaceutical Co., Limited. (Gattuso, Dominick) (Entered: 11/18/2022) (5) |
| Nov 18, 2022 | 22 | MOTION for Pro Hac Vice Appearance of Attorney Scott A. Cunning II, C. Kyle Musgrove, and Elizabeth M. Crompton, each of the law firm of Parker Poe Adams & Bernstein, LLP - filed by Crystal Pharmaceutical (Suzhou) Co., Ltd.. (Gattuso, Dominick) (Entered: 11/18/2022) (6) |
| Nov 16, 2022 | 12 | DECLARATION of Service of Alembic Global Holding SA, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibits A-B)(Joyce, Alexandra) Modified on 11/16/2022 (nms). (Entered: 11/16/2022) (Main Document) (2) |
| Nov 16, 2022 | 13 | DECLARATION of Service of Alembic Pharmaceuticals Limited, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibits A-B)(Joyce, Alexandra) Modified on 11/16/2022 (nms). (Entered: 11/16/2022) (Main Document) (2) |
| Nov 16, 2022 | 14 | DECLARATION of Service of Crystal Pharmaceuticals (Suzhou) Co., Ltd., by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibits A-B)(Joyce, Alexandra) Modified on 11/16/2022 (nms). (Entered: 11/16/2022) (Main Document) (2) |
| Nov 16, 2022 | 15 | DECLARATION of Service of Mylan Laboratories Limited, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 11/16/2022 (nms). (Entered: 11/16/2022) (2) |
| Nov 16, 2022 | 16 | DECLARATION of Service of Mylan Pharmaceuticals Inc., by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 11/16/2022 (nms). (Entered: 11/16/2022) (2) |
| Nov 16, 2022 | 17 | DECLARATION of Service of Nanjing Noratech Pharmaceutical Co., Limited, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibits A-B)(Joyce, Alexandra) Modified on 11/16/2022 (nms). (Entered: 11/16/2022) (Main Document) (2) |
| Nov 16, 2022 | 18 | STIPULATION TO EXTEND TIME for Crystal to Answer the Complaint to December 16, 2022 - filed by Crystal Pharmaceutical (Suzhou) Co., Ltd.. (Gattuso, Dominick) (Entered: 11/16/2022) (3) |
| Nov 16, 2022 | 19 | STIPULATION and Order to Extend Time - filed by Nanjing Noratech Pharmaceutical Co.. (Gattuso, Dominick) Modified on 11/17/2022 (nms). Modified on 11/17/2022 (nms). (Entered: 11/16/2022) (3) |
| Nov 16, 2022 | 20 | STIPULATION and Order to Extend Time to Respond to Complaint, filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc.. (Weinblatt, Richard) Modified on 11/17/2022 (nms). (Entered: 11/16/2022) (2) |
| Nov 16, 2022 | 14 | DECLARATION of Service of Crystal Pharmaceuticals (Suzhou) Co., Ltd., by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibits A-B)(Joyce, Alexandra) Modified on 11/16/2022 (nms). (Entered: 11/16/2022) (Exhibit A-B) (7) |
| Nov 16, 2022 | 17 | DECLARATION of Service of Nanjing Noratech Pharmaceutical Co., Limited, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibits A-B)(Joyce, Alexandra) Modified on 11/16/2022 (nms). (Entered: 11/16/2022) (Exhibit A-B) (7) |
| Nov 16, 2022 | 12 | DECLARATION of Service of Alembic Global Holding SA, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibits A-B)(Joyce, Alexandra) Modified on 11/16/2022 (nms). (Entered: 11/16/2022) (Exhibit A-B) (7) |
| Nov 16, 2022 | 13 | DECLARATION of Service of Alembic Pharmaceuticals Limited, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibits A-B)(Joyce, Alexandra) Modified on 11/16/2022 (nms). (Entered: 11/16/2022) (Exhibit A-B) (7) |
| Nov 11, 2022 | 11 | STIPULATION and Order to Extend Time to Respond to Complaint - filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc.. (Moore, David) Modified on 11/14/2022 (nms). (Entered: 11/11/2022) (2) |
| Oct 31, 2022 | 10 | MOTION for Pro Hac Vice Appearance of Attorney Nicholas N. Kallas, Christina Schwarz, Christopher E. Loh, and Jared L. Stringham - filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certifications for Nicholas N. Kallas, Christina Schwarz, Christopher E. Loh, and Jared L. Stringham)(Silver, Daniel) (Entered: 10/31/2022) (Main Document) (2) |
| Oct 31, 2022 | 10 | MOTION for Pro Hac Vice Appearance of Attorney Nicholas N. Kallas, Christina Schwarz, Christopher E. Loh, and Jared L. Stringham - filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certifications for Nicholas N. Kallas, Christina Schwarz, Christopher E. Loh, and Jared L. Stringham)(Silver, Daniel) (Entered: 10/31/2022) (Certifications for Nicholas N. Kallas, Christina Schwarz, Christopher E. Loh, a) (4) |
| Oct 28, 2022 | 6 | SUMMONS Returned Executed by Novartis Pharmaceuticals Corporation.Alembic Pharmaceuticals, Inc. served on 10/27/2022, answer due 11/17/2022. (Joyce, Alexandra) (Entered: 10/28/2022) (2) |
| Oct 28, 2022 | 7 | SUMMONS Returned Executed by Novartis Pharmaceuticals Corporation.MSN Pharmaceuticals Inc. served on 10/27/2022, answer due 11/17/2022. (Joyce, Alexandra) (Entered: 10/28/2022) (2) |
| Oct 28, 2022 | 8 | SUMMONS Returned Executed by Novartis Pharmaceuticals Corporation.Mylan Laboratories Limited served on 10/27/2022, answer due 11/17/2022. (Joyce, Alexandra) (Entered: 10/28/2022) (2) |
| Oct 28, 2022 | 9 | SUMMONS Returned Executed by Novartis Pharmaceuticals Corporation.Viatris Inc. served on 10/27/2022, answer due 11/17/2022. (Joyce, Alexandra) (Entered: 10/28/2022) (2) |
| Oct 24, 2022 | 1 | Complaint* (1) |
| Oct 24, 2022 | 2 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (smg) (Entered: 10/25/2022) (3) |
| Oct 24, 2022 | 3 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: N/A. Date of Expiration of Patent: 11/08/2026. Stay Deadline: 7/7/2023. (smg) (Entered: 10/25/2022) (3) |
| Oct 24, 2022 | 4 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 11,096,918. (smg) (Entered: 10/25/2022) (1) |
| Oct 24, 2022 | 5 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Novartis AG for Novartis Pharmaceuticals Corporation filed by Novartis Pharmaceuticals Corporation. (smg) (Entered: 10/25/2022) (2) |
